Chemotherapy -overall and by summaries: All cancers

				Any chemotherapy			Alkylating agent (CED, mg/m2)[1]							
			All cases	Yes	No	Unknown	None	1-<4000 mg/m2	4000-<8000 mg/m2	8000-<12000 mg/m2	12000-<16000 mg/m2	16000-<20000 mg/m2	20000+ mg/m2	Unknown
Both sexes	**All cases**		**23716**	**19163**	**4388**	**165**	**10743**	**2868**	**2860**	**2223**	**1273**	**738**	**1218**	**1793**
	Age at baseline	<18	5295	4428	849	18	2469	828	515	443	262	145	248	385
		18-19	1964	1649	302	13	973	247	237	156	90	67	76	118
		20-24	5511	4516	962	33	2656	642	598	466	293	193	302	361
		25-29	5150	4173	937	40	2265	534	682	552	306	174	275	362
		30-34	3566	2801	732	33	1437	388	528	371	212	99	230	301
		35+	2230	1596	606	28	943	229	300	235	110	60	87	266
	Years since diagnosis	5-9	2391	2047	325	19	883	302	264	217	164	80	141	340
		10-14	7681	6228	1412	41	3330	1096	1040	786	416	230	349	434
		15-19	7592	6173	1364	55	3558	863	933	712	383	236	391	516
		20+	6052	4715	1287	50	2972	607	623	508	310	192	337	503
	Age at diagnosis	<1	1789	1258	523	8	919	204	243	110	75	37	88	113
		1-4	7646	6634	975	37	4013	1048	629	563	333	244	360	456
		5-9	5313	4300	981	32	2467	632	543	524	307	184	281	375
		10-14	5026	4006	982	38	1814	592	803	599	348	167	302	401
		15-20	3942	2965	927	50	1530	392	642	427	210	106	187	448
Males	**All cases**		**12555**	**10237**	**2227**	**91**	**5378**	**1532**	**1612**	**1221**	**680**	**433**	**719**	**980**
	Age at baseline	<18	2844	2403	430	11	1236	443	291	244	147	84	163	236
		18-19	1013	860	147	6	469	125	140	89	45	44	39	62
		20-24	2866	2337	508	21	1323	323	339	251	160	115	169	186
		25-29	2820	2309	488	23	1165	304	366	340	178	103	163	201
		30-34	1889	1499	373	17	726	217	308	179	102	56	134	167
		35+	1123	829	281	13	459	120	168	118	48	31	51	128
	Years since diagnosis	5-9	1331	1142	177	12	451	174	159	114	92	50	91	200
		10-14	4084	3356	709	19	1679	573	562	452	231	138	211	238
		15-19	3944	3231	681	32	1746	453	525	398	192	141	218	271
		20+	3196	2508	660	28	1502	332	366	257	165	104	199	271
	Age at diagnosis	<1	907	626	276	5	463	103	128	57	35	19	49	53
		1-4	3967	3465	482	20	1956	548	350	310	179	139	221	264
		5-9	2975	2435	518	22	1266	350	351	309	184	117	164	234
		10-14	2625	2106	498	21	914	297	443	318	183	98	170	202
		15-20	2081	1605	453	23	779	234	340	227	99	60	115	227
Females	**All cases**		**11161**	**8926**	**2161**	**74**	**5365**	**1336**	**1248**	**1002**	**593**	**305**	**499**	**813**
	Age at baseline	<18	2451	2025	419	7	1233	385	224	199	115	61	85	149
		18-19	951	789	155	7	504	122	97	67	45	23	37	56
		20-24	2645	2179	454	12	1333	319	259	215	133	78	133	175
		25-29	2330	1864	449	17	1100	230	316	212	128	71	112	161
		30-34	1677	1302	359	16	711	171	220	192	110	43	96	134
		35+	1107	767	325	15	484	109	132	117	62	29	36	138
	Years since diagnosis	5-9	1060	905	148	7	432	128	105	103	72	30	50	140
		10-14	3597	2872	703	22	1651	523	478	334	185	92	138	196
		15-19	3648	2942	683	23	1812	410	408	314	191	95	173	245
		20+	2856	2207	627	22	1470	275	257	251	145	88	138	232

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
[1] Includes all alkylators with dose info, other than cisplatinum, carboplatin, DTIC and temozolomide
[2] Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Anthracyclines[2]					
			All cases	None	1-<100 mg/m2	100-<250 mg/m2	250-<400 mg/m2	400+ mg/m2	Unknown
Both sexes	**All cases**		**23716**	**12139**	**2165**	**4686**	**2486**	**1300**	**940**
	Age at baseline	<18	5295	2786	618	1046	470	181	194
		18-19	1964	1042	200	395	180	78	69
		20-24	5511	2915	541	1037	544	279	195
		25-29	5150	2579	423	1088	553	295	212
		30-34	3566	1668	261	741	458	288	150
		35+	2230	1149	122	379	281	179	120
	Years since diagnosis	5-9	2391	1044	261	437	333	159	157
		10-14	7681	3780	691	1761	803	391	255
		15-19	7592	3787	724	1529	796	480	276
		20+	6052	3528	489	959	554	270	252
	Age at diagnosis	<1	1789	1139	173	309	75	46	47
		1-4	7646	4160	919	1417	648	240	262
		5-9	5313	2886	472	967	527	262	199
		10-14	5026	2214	382	1157	684	381	208
		15-20	3942	1740	219	836	552	371	224
Males	**All cases**		**12555**	**6288**	**1149**	**2587**	**1301**	**713**	**517**
	Age at baseline	<18	2844	1438	331	596	251	104	124
		18-19	1013	521	106	219	91	38	38
		20-24	2866	1506	270	553	285	153	99
		25-29	2820	1422	230	618	277	166	107
		30-34	1889	844	146	397	252	159	91
		35+	1123	557	66	204	145	93	58
	Years since diagnosis	5-9	1331	556	130	271	180	96	98
		10-14	4084	1975	379	954	411	230	135
		15-19	3944	1932	391	804	435	238	144
		20+	3196	1825	249	558	275	149	140
	Age at diagnosis	<1	907	577	87	165	34	17	27
		1-4	3967	2105	480	748	349	139	146
		5-9	2975	1574	256	609	269	143	124
		10-14	2625	1144	189	631	346	205	110
		15-20	2081	888	137	434	303	209	110
Females	**All cases**		**11161**	**5851**	**1016**	**2099**	**1185**	**587**	**423**
	Age at baseline	<18	2451	1348	287	450	219	77	70
		18-19	951	521	94	176	89	40	31
		20-24	2645	1409	271	484	259	126	96
		25-29	2330	1157	193	470	276	129	105
		30-34	1677	824	115	344	206	129	59
		35+	1107	592	56	175	136	86	62
	Years since diagnosis	5-9	1060	488	131	166	153	63	59
		10-14	3597	1805	312	807	392	161	120
		15-19	3648	1855	333	725	361	242	132
		20+	2856	1703	240	401	279	121	112

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
[1] Includes all alkylators with dose info, other than cisplatinum, carboplatin, DTIC and temozolomide
[2] Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Any chemotherapy			Alkylating agent (CED, mg/m2)[1]							
			All cases	Yes	No	Unknown	None	1-<4000 mg/m2	4000-<8000 mg/m2	8000-<12000 mg/m2	12000-<16000 mg/m2	16000-<20000 mg/m2	20000+ mg/m2	Unknown
	Age at diagnosis	<1	882	632	247	3	456	101	115	53	40	18	39	60
		1-4	3679	3169	493	17	2057	500	279	253	154	105	139	192
		5-9	2338	1865	463	10	1201	282	192	215	123	67	117	141
		10-14	2401	1900	484	17	900	295	360	281	165	69	132	199
		15-20	1861	1360	474	27	751	158	302	200	111	46	72	221

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
[1] Includes all alkylators with dose info, other than cisplatinum, carboplatin, DTIC and temozolomide
[2] Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Anthracyclines[2]					
			All cases	None	1-<100 mg/m2	100-<250 mg/m2	250-<400 mg/m2	400+ mg/m2	Unknown
	Age at diagnosis	<1	882	562	86	144	41	29	20
		1-4	3679	2055	439	669	299	101	116
		5-9	2338	1312	216	358	258	119	75
		10-14	2401	1070	193	526	338	176	98
		15-20	1861	852	82	402	249	162	114

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
[1] Includes all alkylators with dose info, other than cisplatinum, carboplatin, DTIC and temozolomide
[2] Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Any chemotherapy			Alkylating agent (CED, mg/m2)[1]							
			All cases	Yes	No	Unknown	None	1-<4000 mg/m2	4000-<8000 mg/m2	8000-<12000 mg/m2	12000-<16000 mg/m2	16000-<20000 mg/m2	20000+ mg/m2	Unknown
Both sexes	**All cases**		**7302**	**7237**	**18**	**47**	**3164**	**1774**	**749**	**630**	**187**	**110**	**142**	**546**
	Age at baseline	<18	2099	2085	6	8	798	611	194	199	55	32	30	180
		18-19	769	761	3	5	353	182	93	58	18	8	9	48
		20-24	1799	1786	3	10	897	419	160	141	29	20	26	107
		25-29	1471	1461	2	8	652	310	162	135	44	29	41	98
		30-34	779	763	3	13	327	171	98	57	23	14	24	65
		35+	385	381	1	3	137	81	42	40	18	7	12	48
	Years since diagnosis	5-9	906	898	2	6	319	226	75	93	30	10	19	134
		10-14	2444	2423	6	15	902	726	303	228	65	45	38	137
		15-19	2246	2229	5	12	1108	501	250	173	46	16	21	131
		20+	1706	1687	5	14	835	321	121	136	46	39	64	144
	Age at diagnosis	<1	233	228	4	1	77	53	38	25	9	1	7	23
		1-4	3449	3426	8	15	1643	865	282	260	66	48	55	230
		5-9	1767	1750	2	15	828	401	152	147	44	30	34	131
		10-14	1216	1208	2	6	405	317	168	137	43	22	36	88
		15-20	637	625	2	10	211	138	109	61	25	9	10	74
Males	**All cases**		**3855**	**3816**	**11**	**28**	**1597**	**932**	**412**	**342**	**98**	**64**	**96**	**314**
	Age at baseline	<18	1137	1127	5	5	413	327	97	106	33	20	21	120
		18-19	410	407	2	1	185	92	57	29	9	6	7	25
		20-24	895	888	2	5	436	207	85	74	13	12	17	51
		25-29	788	781	1	6	329	172	87	80	22	15	30	53
		30-34	411	401	.	10	157	85	63	30	11	9	14	42
		35+	214	212	1	1	77	49	23	23	10	2	7	23
	Years since diagnosis	5-9	510	506	1	3	164	129	45	45	15	8	13	91
		10-14	1300	1289	4	7	473	378	146	128	42	31	29	73
		15-19	1138	1125	4	9	534	251	145	101	16	8	16	67
		20+	907	896	2	9	426	174	76	68	25	17	38	83
	Age at diagnosis	<1	111	106	4	1	34	23	22	13	7	.	2	10
		1-4	1822	1809	5	8	833	461	151	140	28	23	43	143
		5-9	942	931	1	10	418	203	92	81	30	23	20	75
		10-14	596	592	.	4	187	155	87	69	19	11	23	45
		15-20	384	378	1	5	125	90	60	39	14	7	8	41
Females	**All cases**		**3447**	**3421**	**7**	**19**	**1567**	**842**	**337**	**288**	**89**	**46**	**46**	**232**
	Age at baseline	<18	962	958	1	3	385	284	97	93	22	12	9	60
		18-19	359	354	1	4	168	90	36	29	9	2	2	23
		20-24	904	898	1	5	461	212	75	67	16	8	9	56
		25-29	683	680	1	2	323	138	75	55	22	14	11	45
		30-34	368	362	3	3	170	86	35	27	12	5	10	23
		35+	171	169	.	2	60	32	19	17	8	5	5	25
	Years since diagnosis	5-9	396	392	1	3	155	97	30	48	15	2	6	43
		10-14	1144	1134	2	8	429	348	157	100	23	14	9	64
		15-19	1108	1104	1	3	574	250	105	72	30	8	5	64
		20+	799	791	3	5	409	147	45	68	21	22	26	61
	Age at diagnosis	<1	122	122	.	.	43	30	16	12	2	1	5	13
		1-4	1627	1617	3	7	810	404	131	120	38	25	12	87

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
[1] Includes all alkylators with dose info, other than cisplatinum, carboplatin, DTIC and temozolomide
[2] Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Anthracyclines[2]					
			All cases	None	1-<100 mg/m2	100-<250 mg/m2	250-<400 mg/m2	400+ mg/m2	Unknown
Both sexes	**All cases**		**7302**	**2715**	**1618**	**1766**	**496**	**332**	**375**
	Age at baseline	<18	2099	811	459	487	136	93	113
		18-19	769	309	154	194	57	28	27
		20-24	1799	689	439	400	99	81	91
		25-29	1471	539	315	379	108	61	69
		30-34	779	257	171	201	66	43	41
		35+	385	110	80	105	30	26	34
	Years since diagnosis	5-9	906	280	223	218	63	42	80
		10-14	2444	912	493	683	167	88	101
		15-19	2246	768	526	541	177	139	95
		20+	1706	755	376	324	89	63	99
	Age at diagnosis	<1	233	40	75	72	17	14	15
		1-4	3449	1486	776	701	194	132	160
		5-9	1767	721	366	387	117	87	89
		10-14	1216	320	273	401	106	58	58
		15-20	637	148	128	205	62	41	53
Males	**All cases**		**3855**	**1329**	**849**	**980**	**280**	**191**	**226**
	Age at baseline	<18	1137	397	253	270	75	60	82
		18-19	410	151	82	112	35	13	17
		20-24	895	325	213	208	59	44	46
		25-29	788	286	163	219	54	35	31
		30-34	411	116	94	104	39	26	32
		35+	214	54	44	67	18	13	18
	Years since diagnosis	5-9	510	138	114	140	37	27	54
		10-14	1300	451	268	369	93	60	59
		15-19	1138	357	278	278	105	67	53
		20+	907	383	189	193	45	37	60
	Age at diagnosis	<1	111	18	37	34	5	5	12
		1-4	1822	739	409	383	113	79	99
		5-9	942	345	194	230	65	50	58
		10-14	596	145	124	208	61	32	26
		15-20	384	82	85	125	36	25	31
Females	**All cases**		**3447**	**1386**	**769**	**786**	**216**	**141**	**149**
	Age at baseline	<18	962	414	206	217	61	33	31
		18-19	359	158	72	82	22	15	10
		20-24	904	364	226	192	40	37	45
		25-29	683	253	152	160	54	26	38
		30-34	368	141	77	97	27	17	9
		35+	171	56	36	38	12	13	16
	Years since diagnosis	5-9	396	142	109	78	26	15	26
		10-14	1144	461	225	314	74	28	42
		15-19	1108	411	248	263	72	72	42
		20+	799	372	187	131	44	26	39
	Age at diagnosis	<1	122	22	38	38	12	9	3
		1-4	1627	747	367	318	81	53	61

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
[1] Includes all alkylators with dose info, other than cisplatinum, carboplatin, DTIC and temozolomide
[2] Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Any chemotherapy			Alkylating agent (CED, mg/m2)[1]							
			All cases	Yes	No	Unknown	None	1-<4000 mg/m2	4000-<8000 mg/m2	8000-<12000 mg/m2	12000-<16000 mg/m2	16000-<20000 mg/m2	20000+ mg/m2	Unknown
		5-9	825	819	1	5	410	198	60	66	14	7	14	56
		10-14	620	616	2	2	218	162	81	68	24	11	13	43
		15-20	253	247	1	5	86	48	49	22	11	2	2	33

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
[1] Includes all alkylators with dose info, other than cisplatinum, carboplatin, DTIC and temozolomide
[2] Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Anthracyclines[2]					
			All cases	None	1-<100 mg/m2	100-<250 mg/m2	250-<400 mg/m2	400+ mg/m2	Unknown
		5-9	825	376	172	157	52	37	31
		10-14	620	175	149	193	45	26	32
		15-20	253	66	43	80	26	16	22

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
[1] Includes all alkylators with dose info, other than cisplatinum, carboplatin, DTIC and temozolomide
[2] Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Any chemotherapy			Alkylating agent (CED, mg/m2)[1]							
			All cases	Yes	No	Unknown	None	1-<4000 mg/m2	4000-<8000 mg/m2	8000-<12000 mg/m2	12000-<16000 mg/m2	16000-<20000 mg/m2	20000+ mg/m2	Unknown
Both sexes	**All cases**		**6109**	**6063**	**7**	**39**	**2696**	**1490**	**591**	**538**	**142**	**90**	**124**	**438**
	Age at baseline	<18	1814	1803	3	8	692	518	161	183	43	28	29	160
		18-19	666	662	.	4	313	155	76	54	16	7	8	37
		20-24	1532	1522	1	9	782	360	117	127	26	16	21	83
		25-29	1217	1212	.	5	561	256	128	106	29	25	37	75
		30-34	604	591	2	11	258	139	80	36	14	8	21	48
		35+	276	273	1	2	90	62	29	32	14	6	8	35
	Years since diagnosis	5-9	778	771	2	5	277	183	58	90	28	9	17	116
		10-14	2048	2035	1	12	747	616	245	198	52	38	37	115
		15-19	1853	1841	1	11	951	416	196	142	26	11	15	96
		20+	1430	1416	3	11	721	275	92	108	36	32	55	111
	Age at diagnosis	<1	128	127	.	1	40	29	17	19	5	.	7	11
		1-4	3055	3037	5	13	1477	756	238	235	52	42	47	208
		5-9	1545	1531	.	14	739	351	122	127	39	26	33	108
		10-14	949	946	1	2	312	253	136	111	31	15	32	59
		15-20	432	422	1	9	128	101	78	46	15	7	5	52
Males	**All cases**		**3252**	**3225**	**4**	**23**	**1362**	**784**	**327**	**298**	**77**	**52**	**86**	**266**
	Age at baseline	<18	982	975	2	5	353	275	79	100	27	18	21	109
		18-19	358	357	.	1	163	78	48	27	8	5	7	22
		20-24	762	756	1	5	386	175	58	67	12	9	14	41
		25-29	665	662	.	3	280	146	72	66	16	14	28	43
		30-34	324	315	.	9	128	68	52	20	6	4	13	33
		35+	161	160	1	.	52	42	18	18	8	2	3	18
	Years since diagnosis	5-9	439	435	1	3	141	107	34	44	13	7	13	80
		10-14	1098	1092	1	5	396	316	117	113	35	27	28	66
		15-19	950	940	1	9	463	209	116	86	10	4	11	51
		20+	765	758	1	6	362	152	60	55	19	14	34	69
	Age at diagnosis	<1	64	63	.	1	22	12	11	10	3	.	2	4
		1-4	1603	1593	3	7	736	397	126	128	25	19	39	133
		5-9	833	824	.	9	370	181	75	74	27	20	20	66
		10-14	483	482	.	1	150	124	74	57	14	8	22	34
		15-20	269	263	1	5	84	70	41	29	8	5	3	29
Females	**All cases**		**2857**	**2838**	**3**	**16**	**1334**	**706**	**264**	**240**	**65**	**38**	**38**	**172**
	Age at baseline	<18	832	828	1	3	339	243	82	83	16	10	8	51
		18-19	308	305	.	3	150	77	28	27	8	2	1	15
		20-24	770	766	.	4	396	185	59	60	14	7	7	42
		25-29	552	550	.	2	281	110	56	40	13	11	9	32
		30-34	280	276	2	2	130	71	28	16	8	4	8	15
		35+	115	113	.	2	38	20	11	14	6	4	5	17
	Years since diagnosis	5-9	339	336	1	2	136	76	24	46	15	2	4	36
		10-14	950	943	.	7	351	300	128	85	17	11	9	49
		15-19	903	901	.	2	488	207	80	56	16	7	4	45
		20+	665	658	2	5	359	123	32	53	17	18	21	42
	Age at diagnosis	<1	64	64	.	.	18	17	6	9	2	.	5	7
		1-4	1452	1444	2	6	741	359	112	107	27	23	8	75

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
[1] Includes all alkylators with dose info, other than cisplatinum, carboplatin, DTIC and temozolomide
[2] Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Anthracyclines[2]					
			All cases	None	1-<100 mg/m2	100-<250 mg/m2	250-<400 mg/m2	400+ mg/m2	Unknown
Both sexes	**All cases**		**6109**	**2490**	**1433**	**1264**	**415**	**208**	**299**
	Age at baseline	<18	1814	768	408	367	118	56	97
		18-19	666	291	141	149	47	14	24
		20-24	1532	648	403	275	82	55	69
		25-29	1217	489	279	266	88	39	56
		30-34	604	215	143	136	54	25	31
		35+	276	79	59	71	26	19	22
	Years since diagnosis	5-9	778	239	207	175	50	36	71
		10-14	2048	850	428	503	138	46	83
		15-19	1853	713	470	374	149	74	73
		20+	1430	688	328	212	78	52	72
	Age at diagnosis	<1	128	24	57	25	9	3	10
		1-4	3055	1430	710	523	173	82	137
		5-9	1545	683	341	285	103	63	70
		10-14	949	263	220	300	85	38	43
		15-20	432	90	105	131	45	22	39
Males	**All cases**		**3252**	**1226**	**757**	**719**	**240**	**126**	**184**
	Age at baseline	<18	982	375	227	210	64	36	70
		18-19	358	144	76	84	32	8	14
		20-24	762	310	193	142	48	35	34
		25-29	665	257	146	162	50	23	27
		30-34	324	97	82	74	32	14	25
		35+	161	43	33	47	14	10	14
	Years since diagnosis	5-9	439	120	106	114	29	21	49
		10-14	1098	419	237	279	78	35	50
		15-19	950	332	250	195	93	39	41
		20+	765	355	164	131	40	31	44
	Age at diagnosis	<1	64	9	30	14	2	1	8
		1-4	1603	712	370	287	102	50	82
		5-9	833	330	182	173	60	40	48
		10-14	483	121	105	163	50	24	20
		15-20	269	54	70	82	26	11	26
Females	**All cases**		**2857**	**1264**	**676**	**545**	**175**	**82**	**115**
	Age at baseline	<18	832	393	181	157	54	20	27
		18-19	308	147	65	65	15	6	10
		20-24	770	338	210	133	34	20	35
		25-29	552	232	133	104	38	16	29
		30-34	280	118	61	62	22	11	6
		35+	115	36	26	24	12	9	8
	Years since diagnosis	5-9	339	119	101	61	21	15	22
		10-14	950	431	191	224	60	11	33
		15-19	903	381	220	179	56	35	32
		20+	665	333	164	81	38	21	28
	Age at diagnosis	<1	64	15	27	11	7	2	2
		1-4	1452	718	340	236	71	32	55

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
[1] Includes all alkylators with dose info, other than cisplatinum, carboplatin, DTIC and temozolomide
[2] Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Any chemotherapy			Alkylating agent (CED, mg/m2)[1]							
			All cases	Yes	No	Unknown	None	1-<4000 mg/m2	4000-<8000 mg/m2	8000-<12000 mg/m2	12000-<16000 mg/m2	16000-<20000 mg/m2	20000+ mg/m2	Unknown
		5-9	712	707	.	5	369	170	47	53	12	6	13	42
		10-14	466	464	1	1	162	129	62	54	17	7	10	25
		15-20	163	159	.	4	44	31	37	17	7	2	2	23

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
[1] Includes all alkylators with dose info, other than cisplatinum, carboplatin, DTIC and temozolomide
[2] Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Anthracyclines[2]					
			All cases	None	1-<100 mg/m2	100-<250 mg/m2	250-<400 mg/m2	400+ mg/m2	Unknown
		5-9	712	353	159	112	43	23	22
		10-14	466	142	115	137	35	14	23
		15-20	163	36	35	49	19	11	13

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
[1] Includes all alkylators with dose info, other than cisplatinum, carboplatin, DTIC and temozolomide
[2] Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Any chemotherapy			Alkylating agent (CED, mg/m2)[1]							
			All cases	Yes	No	Unknown	None	1-<4000 mg/m2	4000-<8000 mg/m2	8000-<12000 mg/m2	12000-<16000 mg/m2	16000-<20000 mg/m2	20000+ mg/m2	Unknown
Both sexes	**All cases**		**882**	**871**	**6**	**5**	**370**	**193**	**121**	**69**	**37**	**13**	**11**	**68**
	Age at baseline	<18	225	223	2	.	88	70	30	14	10	3	1	9
		18-19	82	79	2	1	31	19	15	4	2	1	1	9
		20-24	193	191	1	1	90	40	30	9	2	3	2	17
		25-29	188	187	.	1	71	36	29	21	11	3	3	14
		30-34	121	119	1	1	50	19	10	17	8	3	3	11
		35+	73	72	.	1	40	9	7	4	4	.	1	8
	Years since diagnosis	5-9	81	80	.	1	26	31	14	.	1	.	2	7
		10-14	307	303	3	1	131	78	43	22	13	6	1	13
		15-19	304	301	2	1	129	58	43	26	16	3	3	26
		20+	190	187	1	2	84	26	21	21	7	4	5	22
	Age at diagnosis	<1	90	87	3	.	32	18	20	6	4	1	.	9
		1-4	301	299	1	1	130	79	38	22	11	4	4	13
		5-9	166	164	1	1	72	36	22	15	1	3	1	16
		10-14	186	183	.	3	70	39	22	19	11	5	4	16
		15-20	139	138	1	.	66	21	19	7	10	.	2	14
Males	**All cases**		**430**	**424**	**3**	**3**	**186**	**100**	**61**	**29**	**16**	**6**	**5**	**27**
	Age at baseline	<18	122	120	2	.	52	41	15	5	4	1	.	4
		18-19	42	41	1	.	17	10	8	2	1	1	.	3
		20-24	92	92	.	.	38	22	18	5	1	2	1	5
		25-29	82	81	.	1	37	16	11	8	4	.	2	4
		30-34	58	57	.	1	22	9	6	7	4	2	1	7
		35+	34	33	.	1	20	2	3	2	2	.	1	4
	Years since diagnosis	5-9	47	47	.	.	16	16	9	.	1	.	.	5
		10-14	152	149	2	1	69	45	17	8	7	3	1	2
		15-19	141	140	1	.	55	31	23	14	4	2	2	10
		20+	90	88	.	2	46	8	12	7	4	1	2	10
	Age at diagnosis	<1	39	36	3	.	11	8	10	3	4	.	.	3
		1-4	165	165	.	.	77	46	21	10	2	2	2	5
		5-9	76	75	.	1	36	18	11	4	.	2	.	5
		10-14	75	73	.	2	29	17	7	8	4	2	1	7
		15-20	75	75	.	.	33	11	12	4	6	.	2	7
Females	**All cases**		**452**	**447**	**3**	**2**	**184**	**93**	**60**	**40**	**21**	**7**	**6**	**41**
	Age at baseline	<18	103	103	.	.	36	29	15	9	6	2	1	5
		18-19	40	38	1	1	14	9	7	2	1	.	1	6
		20-24	101	99	1	1	52	18	12	4	1	1	1	12
		25-29	106	106	.	.	34	20	18	13	7	3	1	10
		30-34	63	62	1	.	28	10	4	10	4	1	2	4
		35+	39	39	.	.	20	7	4	2	2	.	.	4
	Years since diagnosis	5-9	34	33	.	1	10	15	5	.	.	.	2	2
		10-14	155	154	1	.	62	33	26	14	6	3	.	11
		15-19	163	161	1	1	74	27	20	12	12	1	1	16
		20+	100	99	1	.	38	18	9	14	3	3	3	12
	Age at diagnosis	<1	51	51	.	.	21	10	10	3	.	1	.	6
		1-4	136	134	1	1	53	33	17	12	9	2	2	8

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
[1] Includes all alkylators with dose info, other than cisplatinum, carboplatin, DTIC and temozolomide
[2] Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Anthracyclines[2]					
			All cases	None	1-<100 mg/m2	100-<250 mg/m2	250-<400 mg/m2	400+ mg/m2	Unknown
Both sexes	**All cases**		**882**	**59**	**154**	**440**	**68**	**105**	**56**
	Age at baseline	<18	225	13	45	109	13	33	12
		18-19	82	8	11	37	10	13	3
		20-24	193	8	26	107	13	21	18
		25-29	188	8	32	103	18	18	9
		30-34	121	12	22	56	12	14	5
		35+	73	10	18	28	2	6	9
	Years since diagnosis	5-9	81	6	15	39	9	4	8
		10-14	307	13	55	164	26	36	13
		15-19	304	15	48	141	25	58	17
		20+	190	25	36	96	8	7	18
	Age at diagnosis	<1	90	11	17	44	6	11	1
		1-4	301	14	52	155	18	43	19
		5-9	166	11	22	87	11	20	15
		10-14	186	10	42	89	17	17	11
		15-20	139	13	21	65	16	14	10
Males	**All cases**		**430**	**26**	**76**	**213**	**32**	**54**	**29**
	Age at baseline	<18	122	8	23	51	9	22	9
		18-19	42	4	5	22	3	5	3
		20-24	92	2	14	53	8	7	8
		25-29	82	3	14	50	3	10	2
		30-34	58	5	11	23	7	8	4
		35+	34	4	9	14	2	2	3
	Years since diagnosis	5-9	47	3	7	22	6	4	5
		10-14	152	5	28	78	13	22	6
		15-19	141	9	24	65	10	24	9
		20+	90	9	17	48	3	4	9
	Age at diagnosis	<1	39	6	7	18	3	4	1
		1-4	165	7	30	78	9	28	13
		5-9	76	4	10	46	3	7	6
		10-14	75	5	15	36	8	6	5
		15-20	75	4	14	35	9	9	4
Females	**All cases**		**452**	**33**	**78**	**227**	**36**	**51**	**27**
	Age at baseline	<18	103	5	22	58	4	11	3
		18-19	40	4	6	15	7	8	.
		20-24	101	6	12	54	5	14	10
		25-29	106	5	18	53	15	8	7
		30-34	63	7	11	33	5	6	1
		35+	39	6	9	14	.	4	6
	Years since diagnosis	5-9	34	3	8	17	3	.	3
		10-14	155	8	27	86	13	14	7
		15-19	163	6	24	76	15	34	8
		20+	100	16	19	48	5	3	9
	Age at diagnosis	<1	51	5	10	26	3	7	.
		1-4	136	7	22	77	9	15	6

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
[1] Includes all alkylators with dose info, other than cisplatinum, carboplatin, DTIC and temozolomide
[2] Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Any chemotherapy			Alkylating agent (CED, mg/m2)[1]							
			All cases	Yes	No	Unknown	None	1-<4000 mg/m2	4000-<8000 mg/m2	8000-<12000 mg/m2	12000-<16000 mg/m2	16000-<20000 mg/m2	20000+ mg/m2	Unknown
		5-9	90	89	1	.	36	18	11	11	1	1	1	11
		10-14	111	110	.	1	41	22	15	11	7	3	3	9
		15-20	64	63	1	.	33	10	7	3	4	.	.	7

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
[1] Includes all alkylators with dose info, other than cisplatinum, carboplatin, DTIC and temozolomide
[2] Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Anthracyclines[2]				
			All cases	None	1-<100 mg/m2	100-<250 mg/m2	250-<400 mg/m2	400+ mg/m2	Unknown
		5-9	90	7	12	41	8	13	9
		10-14	111	5	27	53	9	11	6
		15-20	64	9	7	30	7	5	6

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
[1] Includes all alkylators with dose info, other than cisplatinum, carboplatin, DTIC and temozolomide
[2] Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Any chemotherapy			Alkylating agent (CED, mg/m2)[1]							
			All cases	Yes	No	Unknown	None	1-<4000 mg/m2	4000-<8000 mg/m2	8000-<12000 mg/m2	12000-<16000 mg/m2	16000-<20000 mg/m2	20000+ mg/m2	Unknown
Both sexes	**All cases**		**4211**	**1629**	**2543**	**39**	**2964**	**111**	**154**	**319**	**228**	**114**	**114**	**207**
	Age at baseline	<18	891	440	447	4	552	24	41	68	70	29	44	63
		18-19	349	164	179	6	233	6	18	26	19	12	15	20
		20-24	1103	444	650	9	751	38	40	89	58	42	29	56
		25-29	1029	373	645	11	740	27	34	88	62	19	17	42
		30-34	586	157	426	3	470	15	15	40	13	9	6	18
		35+	253	51	196	6	218	1	6	8	6	3	3	8
	Years since diagnosis	5-9	430	218	207	5	237	11	15	32	49	15	18	53
		10-14	1427	561	855	11	1007	36	63	127	73	34	34	53
		15-19	1335	512	808	15	952	34	51	93	59	43	43	60
		20+	1019	338	673	8	768	30	25	67	47	22	19	41
	Age at diagnosis	<1	206	121	84	1	119	7	15	7	11	9	23	15
		1-4	1231	558	664	9	823	36	39	81	78	52	58	64
		5-9	1331	520	802	9	918	42	54	132	77	30	14	64
		10-14	1005	316	679	10	756	22	37	77	45	17	11	40
		15-20	438	114	314	10	348	4	9	22	17	6	8	24
Males	**All cases**		**2292**	**945**	**1321**	**26**	**1554**	**52**	**89**	**192**	**136**	**75**	**68**	**126**
	Age at baseline	<18	494	258	232	4	281	13	27	39	43	21	31	39
		18-19	177	84	89	4	119	3	10	15	8	5	6	11
		20-24	590	260	325	5	380	17	24	56	36	27	19	31
		25-29	584	233	346	5	406	14	17	59	41	14	8	25
		30-34	312	81	229	2	255	5	6	19	6	5	3	13
		35+	135	29	100	6	113	.	5	4	2	3	1	7
	Years since diagnosis	5-9	244	123	117	4	133	6	11	17	26	10	10	31
		10-14	768	329	433	6	509	19	35	79	47	24	22	33
		15-19	726	301	415	10	498	15	30	57	37	27	25	37
		20+	554	192	356	6	414	12	13	39	26	14	11	25
	Age at diagnosis	<1	121	72	48	1	66	4	12	2	5	7	18	7
		1-4	652	312	335	5	414	16	19	54	48	33	36	32
		5-9	741	322	414	5	488	20	32	78	48	20	7	48
		10-14	531	174	349	8	392	9	21	47	27	10	2	23
		15-20	247	65	175	7	194	3	5	11	8	5	5	16
Females	**All cases**		**1919**	**684**	**1222**	**13**	**1410**	**59**	**65**	**127**	**92**	**39**	**46**	**81**
	Age at baseline	<18	397	182	215	.	271	11	14	29	27	8	13	24
		18-19	172	80	90	2	114	3	8	11	11	7	9	9
		20-24	513	184	325	4	371	21	16	33	22	15	10	25
		25-29	445	140	299	6	334	13	17	29	21	5	9	17
		30-34	274	76	197	1	215	10	9	21	7	4	3	5
		35+	118	22	96	.	105	1	1	4	4	.	2	1
	Years since diagnosis	5-9	186	95	90	1	104	5	4	15	23	5	8	22
		10-14	659	232	422	5	498	17	28	48	26	10	12	20
		15-19	609	211	393	5	454	19	21	36	22	16	18	23
		20+	465	146	317	2	354	18	12	28	21	8	8	16
	Age at diagnosis	<1	85	49	36	.	53	3	3	5	6	2	5	8

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
[1] Includes all alkylators with dose info, other than cisplatinum, carboplatin, DTIC and temozolomide
[2] Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Anthracyclines[2]				
			All cases	None	100-<250 mg/m2	250-<400 mg/m2	400+ mg/m2	Unknown
Both sexes	**All cases**		**4211**	**4145**	**13**	**17**	**3**	**33**
	Age at baseline	<18	891	883	1	2	1	4
		18-19	349	345	.	1	.	3
		20-24	1103	1083	5	4	2	9
		25-29	1029	1010	4	4	.	11
		30-34	586	576	3	5	.	2
		35+	253	248	.	1	.	4
	Years since diagnosis	5-9	430	424	2	1	.	3
		10-14	1427	1412	6	1	1	7
		15-19	1335	1303	4	11	2	15
		20+	1019	1006	1	4	.	8
	Age at diagnosis	<1	206	205	.	.	1	.
		1-4	1231	1215	2	4	1	9
		5-9	1331	1309	3	8	1	10
		10-14	1005	987	5	3	.	10
		15-20	438	429	3	2	.	4
Males	**All cases**		**2292**	**2253**	**7**	**9**	**2**	**21**
	Age at baseline	<18	494	488	1	1	1	3
		18-19	177	176	.	.	.	1
		20-24	590	577	3	3	1	6
		25-29	584	574	2	2	.	6
		30-34	312	306	1	3	.	2
		35+	135	132	.	.	.	3
	Years since diagnosis	5-9	244	240	1	1	.	2
		10-14	768	759	4	1	1	3
		15-19	726	707	2	5	1	11
		20+	554	547	.	2	.	5
	Age at diagnosis	<1	121	120	.	.	1	.
		1-4	652	647	.	1	.	4
		5-9	741	725	3	5	1	7
		10-14	531	520	2	2	.	7
		15-20	247	241	2	1	.	3
Females	**All cases**		**1919**	**1892**	**6**	**8**	**1**	**12**
	Age at baseline	<18	397	395	.	1	.	1
		18-19	172	169	.	1	.	2
		20-24	513	506	2	1	1	3
		25-29	445	436	2	2	.	5
		30-34	274	270	2	2	.	.
		35+	118	116	.	1	.	1
	Years since diagnosis	5-9	186	184	1	.	.	1
		10-14	659	653	2	.	.	4
		15-19	609	596	2	6	1	4
		20+	465	459	1	2	.	3
	Age at diagnosis	<1	85	85	.	.	.	.

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
[1] Includes all alkylators with dose info, other than cisplatinum, carboplatin, DTIC and temozolomide
[2] Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Any chemotherapy			Alkylating agent (CED, mg/m2)[1]							
			All cases	Yes	No	Unknown	None	1-<4000 mg/m2	4000-<8000 mg/m2	8000-<12000 mg/m2	12000-<16000 mg/m2	16000-<20000 mg/m2	20000+ mg/m2	Unknown
		1-4	579	246	329	4	409	20	20	27	30	19	22	32
		5-9	590	198	388	4	430	22	22	54	29	10	7	16
		10-14	474	142	330	2	364	13	16	30	18	7	9	17
		15-20	191	49	139	3	154	1	4	11	9	1	3	8

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
[1] Includes all alkylators with dose info, other than cisplatinum, carboplatin, DTIC and temozolomide
[2] Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Anthracyclines[2]				
			All cases	None	100-<250 mg/m2	250-<400 mg/m2	400+ mg/m2	Unknown
		1-4	579	568	2	3	1	5
		5-9	590	584	.	3	.	3
		10-14	474	467	3	1	.	3
		15-20	191	188	1	1	.	1

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
[1] Includes all alkylators with dose info, other than cisplatinum, carboplatin, DTIC and temozolomide
[2] Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Any chemotherapy			Alkylating agent (CED, mg/m2)[1]							
			All cases	Yes	No	Unknown	None	1-<4000 mg/m2	4000-<8000 mg/m2	8000-<12000 mg/m2	12000-<16000 mg/m2	16000-<20000 mg/m2	20000+ mg/m2	Unknown
Both sexes	**All cases**		**2528**	**639**	**1868**	**21**	**2162**	**43**	**38**	**66**	**66**	**27**	**36**	**90**
	Age at baseline	<18	493	180	311	2	393	10	10	15	20	9	12	24
		18-19	202	70	129	3	170	3	3	6	8	1	4	7
		20-24	668	167	495	6	572	12	13	13	14	8	11	25
		25-29	636	146	484	6	551	13	6	19	15	6	7	19
		30-34	360	55	303	2	321	4	4	10	7	2	1	11
		35+	169	21	146	2	155	1	2	3	2	1	1	4
	Years since diagnosis	5-9	220	77	142	1	160	4	5	11	16	5	4	15
		10-14	840	233	600	7	719	14	13	24	24	7	12	27
		15-19	784	185	590	9	687	15	10	13	14	7	10	28
		20+	684	144	536	4	596	10	10	18	12	8	10	20
	Age at diagnosis	<1	145	83	62	.	94	6	8	3	7	5	12	10
		1-4	748	230	511	7	639	12	10	15	20	12	14	26
		5-9	753	159	588	6	661	12	7	24	16	3	4	26
		10-14	603	110	490	3	530	11	10	16	12	4	3	17
		15-20	279	57	217	5	238	2	3	8	11	3	3	11
Males	**All cases**		**1315**	**359**	**945**	**11**	**1097**	**23**	**23**	**27**	**40**	**23**	**21**	**61**
	Age at baseline	<18	258	104	152	2	189	5	6	7	16	8	10	17
		18-19	102	36	64	2	85	2	3	3	2	1	1	5
		20-24	329	92	235	2	274	8	8	6	7	6	5	15
		25-29	356	89	265	2	305	7	3	10	10	5	4	12
		30-34	181	25	155	1	165	1	1	.	3	2	.	9
		35+	89	13	74	2	79	.	2	1	2	1	1	3
	Years since diagnosis	5-9	118	41	77	.	86	2	5	4	8	4	3	6
		10-14	438	136	299	3	358	8	5	12	19	7	8	21
		15-19	396	100	290	6	339	9	6	5	6	7	4	20
		20+	363	82	279	2	314	4	7	6	7	5	6	14
	Age at diagnosis	<1	81	50	31	.	46	4	7	2	3	4	8	7
		1-4	378	126	249	3	308	7	6	9	14	10	8	16
		5-9	397	96	297	4	343	6	4	9	10	2	3	20
		10-14	304	56	246	2	267	5	5	4	8	4	.	11
		15-20	155	31	122	2	133	1	1	3	5	3	2	7
Females	**All cases**		**1213**	**280**	**923**	**10**	**1065**	**20**	**15**	**39**	**26**	**4**	**15**	**29**
	Age at baseline	<18	235	76	159	.	204	5	4	8	4	1	2	7
		18-19	100	34	65	1	85	1	.	3	6	.	3	2
		20-24	339	75	260	4	298	4	5	7	7	2	6	10
		25-29	280	57	219	4	246	6	3	9	5	1	3	7
		30-34	179	30	148	1	156	3	3	10	4	.	1	2
		35+	80	8	72	.	76	1	.	2	.	.	.	1
	Years since diagnosis	5-9	102	36	65	1	74	2	.	7	8	1	1	9
		10-14	402	97	301	4	361	6	8	12	5	.	4	6
		15-19	388	85	300	3	348	6	4	8	8	.	6	8
		20+	321	62	257	2	282	6	3	12	5	3	4	6
	Age at diagnosis	<1	64	33	31	.	48	2	1	1	4	1	4	3
		1-4	370	104	262	4	331	5	4	6	6	2	6	10

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
[1] Includes all alkylators with dose info, other than cisplatinum, carboplatin, DTIC and temozolomide
[2] Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Anthracyclines[2]				
			All cases	None	100-<250 mg/m2	250-<400 mg/m2	400+ mg/m2	Unknown
Both sexes	**All cases**		**2528**	**2503**	**4**	**1**	**1**	**19**
	Age at baseline	<18	493	491	.	.	.	2
		18-19	202	200	.	.	.	2
		20-24	668	657	4	1	1	5
		25-29	636	629	.	.	.	7
		30-34	360	359	.	.	.	1
		35+	169	167	.	.	.	2
	Years since diagnosis	5-9	220	219	1	.	.	.
		10-14	840	833	2	.	.	5
		15-19	784	773	1	1	1	8
		20+	684	678	.	.	.	6
	Age at diagnosis	<1	145	145	.	.	.	.
		1-4	748	740	1	.	.	7
		5-9	753	744	1	1	1	6
		10-14	603	598	1	.	.	4
		15-20	279	276	1	.	.	2
Males	**All cases**		**1315**	**1301**	**2**	**1**	**1**	**10**
	Age at baseline	<18	258	256	.	.	.	2
		18-19	102	101	.	.	.	1
		20-24	329	323	2	1	1	2
		25-29	356	353	.	.	.	3
		30-34	181	180	.	.	.	1
		35+	89	88	.	.	.	1
	Years since diagnosis	5-9	118	118	.	.	.	.
		10-14	438	434	2	.	.	2
		15-19	396	389	.	1	1	5
		20+	363	360	.	.	.	3
	Age at diagnosis	<1	81	81	.	.	.	.
		1-4	378	375	.	.	.	3
		5-9	397	390	1	1	1	4
		10-14	304	301	1	.	.	2
		15-20	155	154	.	.	.	1
Females	**All cases**		**1213**	**1202**	**2**	**.**	**.**	**9**
	Age at baseline	<18	235	235	.	.	.	.
		18-19	100	99	.	.	.	1
		20-24	339	334	2	.	.	3
		25-29	280	276	.	.	.	4
		30-34	179	179	.	.	.	.
		35+	80	79	.	.	.	1
	Years since diagnosis	5-9	102	101	1	.	.	.
		10-14	402	399	.	.	.	3
		15-19	388	384	1	.	.	3
		20+	321	318	.	.	.	3
	Age at diagnosis	<1	64	64	.	.	.	.
		1-4	370	365	1	.	.	4

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
[1] Includes all alkylators with dose info, other than cisplatinum, carboplatin, DTIC and temozolomide
[2] Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Any chemotherapy			Alkylating agent (CED, mg/m2)[1]							
			All cases	Yes	No	Unknown	None	1-<4000 mg/m2	4000-<8000 mg/m2	8000-<12000 mg/m2	12000-<16000 mg/m2	16000-<20000 mg/m2	20000+ mg/m2	Unknown
		5-9	356	63	291	2	318	6	3	15	6	1	1	6
		10-14	299	54	244	1	263	6	5	12	4	.	3	6
		15-20	124	26	95	3	105	1	2	5	6	.	1	4

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
[1] Includes all alkylators with dose info, other than cisplatinum, carboplatin, DTIC and temozolomide
[2] Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Anthracyclines[2]				
			All cases	None	100-<250 mg/m2	250-<400 mg/m2	400+ mg/m2	Unknown
		5-9	356	354	.	.	.	2
		10-14	299	297	.	.	.	2
		15-20	124	122	1	.	.	1

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
[1] Includes all alkylators with dose info, other than cisplatinum, carboplatin, DTIC and temozolomide
[2] Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Any chemotherapy			Alkylating agent (CED, mg/m2) [1]							
			All cases	Yes	No	Unknown	None	1-<4000 mg/m2	4000-<8000 mg/m2	8000-<12000 mg/m2	12000-<16000 mg/m2	16000-<20000 mg/m2	20000+ mg/m2	Unknown
Both sexes	**All cases**		**983**	**753**	**218**	**12**	**281**	**55**	**94**	**212**	**125**	**67**	**59**	**90**
	Age at baseline	<18	233	184	47	2	56	11	24	38	33	14	24	33
		18-19	77	58	16	3	20	2	9	18	7	6	7	8
		20-24	276	223	50	3	60	21	24	67	39	28	12	25
		25-29	236	183	51	2	68	11	25	60	37	10	9	16
		30-34	127	87	40	.	58	10	10	26	6	7	5	5
		35+	34	18	14	2	19	.	2	3	3	2	2	3
	Years since diagnosis	5-9	120	98	18	4	23	3	7	17	24	6	12	28
		10-14	334	259	72	3	84	17	42	85	40	25	18	23
		15-19	325	245	77	3	99	17	31	71	34	26	23	24
		20+	204	151	51	2	75	18	14	39	27	10	6	15
	Age at diagnosis	<1	23	19	3	1	4	1	4	2	1	1	7	3
		1-4	280	222	56	2	69	18	21	49	36	25	31	31
		5-9	402	308	92	2	117	29	42	97	55	25	8	29
		10-14	220	166	50	4	69	7	23	54	28	13	8	18
		15-20	58	38	17	3	22	.	4	10	5	3	5	9
Males	**All cases**		**600**	**467**	**123**	**10**	**170**	**24**	**55**	**147**	**80**	**41**	**32**	**51**
	Age at baseline	<18	141	114	25	2	32	6	18	27	20	7	13	18
		18-19	44	33	9	2	13	1	4	12	3	3	3	5
		20-24	178	143	32	3	38	8	14	47	29	19	10	13
		25-29	145	120	24	1	38	5	13	44	25	7	3	10
		30-34	71	47	24	.	36	4	4	16	3	3	3	2
		35+	21	10	9	2	13	.	2	1	.	2	.	3
	Years since diagnosis	5-9	73	58	11	4	15	1	5	12	15	2	5	18
		10-14	197	161	34	2	42	9	25	60	24	15	11	11
		15-19	207	157	48	2	66	6	19	48	24	17	13	14
		20+	123	91	30	2	47	8	6	27	17	7	3	8
	Age at diagnosis	<1	16	12	3	1	4	.	4	.	1	1	6	.
		1-4	168	137	29	2	40	7	9	40	24	16	17	15
		5-9	256	199	56	1	74	14	26	64	36	16	4	22
		10-14	125	96	26	3	39	3	14	37	16	6	2	8
		15-20	35	23	9	3	13	.	2	6	3	2	3	6
Females	**All cases**		**383**	**286**	**95**	**2**	**111**	**31**	**39**	**65**	**45**	**26**	**27**	**39**
	Age at baseline	<18	92	70	22	.	24	5	6	11	13	7	11	15
		18-19	33	25	7	1	7	1	5	6	4	3	4	3
		20-24	98	80	18	.	22	13	10	20	10	9	2	12
		25-29	91	63	27	1	30	6	12	16	12	3	6	6
		30-34	56	40	16	.	22	6	6	10	3	4	2	3
		35+	13	8	5	.	6	.	.	2	3	.	2	.
	Years since diagnosis	5-9	47	40	7	.	8	2	2	5	9	4	7	10
		10-14	137	98	38	1	42	8	17	25	16	10	7	12
		15-19	118	88	29	1	33	11	12	23	10	9	10	10
		20+	81	60	21	.	28	10	8	12	10	3	3	7
	Age at diagnosis	<1	7	7	.	.	.	1	.	2	.	.	1	3
		1-4	112	85	27	.	29	11	12	9	12	9	14	16

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
[1] Includes all alkylators with dose info, other than cisplatinum, carboplatin, DTIC and temozolomide
[2] Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Anthracyclines[2]			
			All cases	None	100-<250 mg/m2	250-<400 mg/m2	Unknown
Both sexes	**All cases**		**983**	**950**	**9**	**14**	**10**
	Age at baseline	<18	233	229	1	1	2
		18-19	77	76	.	.	1
		20-24	276	268	1	3	4
		25-29	236	226	4	4	2
		30-34	127	119	3	5	.
		35+	34	32	.	1	1
	Years since diagnosis	5-9	120	116	1	.	3
		10-14	334	327	4	1	2
		15-19	325	309	3	9	4
		20+	204	198	1	4	1
	Age at diagnosis	<1	23	23	.	.	.
		1-4	280	274	1	3	2
		5-9	402	390	2	6	4
		10-14	220	210	4	3	3
		15-20	58	53	2	2	1
Males	**All cases**		**600**	**581**	**5**	**7**	**7**
	Age at baseline	<18	141	139	1	.	1
		18-19	44	44	.	.	.
		20-24	178	171	1	2	4
		25-29	145	140	2	2	1
		30-34	71	67	1	3	.
		35+	21	20	.	.	1
	Years since diagnosis	5-9	73	70	1	.	2
		10-14	197	193	2	1	1
		15-19	207	198	2	4	3
		20+	123	120	.	2	1
	Age at diagnosis	<1	16	16	.	.	.
		1-4	168	166	.	1	1
		5-9	256	248	2	3	3
		10-14	125	120	1	2	2
		15-20	35	31	2	1	1
Females	**All cases**		**383**	**369**	**4**	**7**	**3**
	Age at baseline	<18	92	90	.	1	1
		18-19	33	32	.	.	1
		20-24	98	97	.	1	.
		25-29	91	86	2	2	1
		30-34	56	52	2	2	.
		35+	13	12	.	1	.
	Years since diagnosis	5-9	47	46	.	.	1
		10-14	137	134	2	.	1
		15-19	118	111	1	5	1
		20+	81	78	1	2	.
	Age at diagnosis	<1	7	7	.	.	.
		1-4	112	108	1	2	1

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
[1] Includes all alkylators with dose info, other than cisplatinum, carboplatin, DTIC and temozolomide
[2] Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Any chemotherapy			Alkylating agent (CED, mg/m2)[1]							
			All cases	Yes	No	Unknown	None	1-<4000 mg/m2	4000-<8000 mg/m2	8000-<12000 mg/m2	12000-<16000 mg/m2	16000-<20000 mg/m2	20000+ mg/m2	Unknown
		5-9	146	109	36	1	43	15	16	33	19	9	4	7
		10-14	95	70	24	1	30	4	9	17	12	7	6	10
		15-20	23	15	8	.	9	.	2	4	2	1	2	3

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
[1] Includes all alkylators with dose info, other than cisplatinum, carboplatin, DTIC and temozolomide
[2] Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Anthracyclines[2]			
			All cases	None	100-<250 mg/m2	250-<400 mg/m2	Unknown
		5-9	146	142	.	3	1
		10-14	95	90	3	1	1
		15-20	23	22	.	1	.

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
[1] Includes all alkylators with dose info, other than cisplatinum, carboplatin, DTIC and temozolomide
[2] Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Any chemotherapy			Alkylating agent (CED, mg/m2)[1]							
			All cases	Yes	No	Unknown	None	1-<4000 mg/m2	4000-<8000 mg/m2	8000-<12000 mg/m2	12000-<16000 mg/m2	16000-<20000 mg/m2	20000+ mg/m2	Unknown
Both sexes	**All cases**		**2839**	**2141**	**662**	**36**	**940**	**140**	**614**	**378**	**243**	**65**	**82**	**377**
	Age at baseline	<18	55	45	10	.	20	.	13	7	3	2	3	7
		18-19	54	44	10	.	17	1	17	7	6	.	1	5
		20-24	330	268	56	6	93	11	79	41	46	7	11	42
		25-29	734	589	137	8	211	21	209	110	67	21	19	76
		30-34	867	677	179	11	268	61	179	112	78	20	32	117
		35+	799	518	270	11	331	46	117	101	43	15	16	130
	Years since diagnosis	5-9	222	177	41	4	71	5	38	21	21	8	14	44
		10-14	866	683	173	10	268	31	241	119	81	15	18	93
		15-19	933	726	194	13	301	53	192	130	81	26	22	128
		20+	818	555	254	9	300	51	143	108	60	16	28	112
	Age at diagnosis	1-4	70	50	19	1	26	1	18	11	7	2	.	5
		5-9	356	282	72	2	110	18	85	46	39	8	11	39
		10-14	1029	833	184	12	276	46	263	156	116	25	32	115
		15-20	1384	976	387	21	528	75	248	165	81	30	39	218
Males	**All cases**		**1468**	**1111**	**340**	**17**	**483**	**80**	**302**	**187**	**127**	**45**	**48**	**196**
	Age at baseline	<18	42	34	8	.	16	.	11	4	1	2	3	5
		18-19	43	34	9	.	14	1	13	6	4	.	1	4
		20-24	210	166	39	5	62	8	54	19	27	5	8	27
		25-29	402	318	79	5	120	15	88	68	42	15	10	44
		30-34	433	339	91	3	133	38	86	48	37	13	16	62
		35+	338	220	114	4	138	18	50	42	16	10	10	54
	Years since diagnosis	5-9	127	101	23	3	39	4	20	11	12	7	10	24
		10-14	440	346	90	4	139	16	111	61	41	9	13	50
		15-19	495	389	99	7	155	32	97	65	44	17	11	74
		20+	406	275	128	3	150	28	74	50	30	12	14	48
	Age at diagnosis	1-4	52	37	14	1	20	1	13	7	5	1	.	5
		5-9	261	205	54	2	81	15	63	30	28	8	6	30
		10-14	525	420	99	6	153	24	130	76	57	15	16	54
		15-20	630	449	173	8	229	40	96	74	37	21	26	107
Females	**All cases**		**1371**	**1030**	**322**	**19**	**457**	**60**	**312**	**191**	**116**	**20**	**34**	**181**
	Age at baseline	<18	13	11	2	.	4	.	2	3	2	.	.	2
		18-19	11	10	1	.	3	.	4	1	2	.	.	1
		20-24	120	102	17	1	31	3	25	22	19	2	3	15
		25-29	332	271	58	3	91	6	121	42	25	6	9	32
		30-34	434	338	88	8	135	23	93	64	41	7	16	55
		35+	461	298	156	7	193	28	67	59	27	5	6	76
	Years since diagnosis	5-9	95	76	18	1	32	1	18	10	9	1	4	20
		10-14	426	337	83	6	129	15	130	58	40	6	5	43
		15-19	438	337	95	6	146	21	95	65	37	9	11	54
		20+	412	280	126	6	150	23	69	58	30	4	14	64
	Age at diagnosis	1-4	18	13	5	.	6	.	5	4	2	1	.	.
		5-9	95	77	18	.	29	3	22	16	11	.	5	9
		10-14	504	413	85	6	123	22	133	80	59	10	16	61
		15-20	754	527	214	13	299	35	152	91	44	9	13	111

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
[1] Includes all alkylators with dose info, other than cisplatinum, carboplatin, DTIC and temozolomide
[2] Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Anthracyclines[2]					
			All cases	None	1-<100 mg/m2	100-<250 mg/m2	250-<400 mg/m2	400+ mg/m2	Unknown
Both sexes	**All cases**		**2839**	**1433**	**81**	**874**	**320**	**34**	**97**
	Age at baseline	<18	55	19	1	21	12	.	2
		18-19	54	21	2	19	10	1	1
		20-24	330	128	16	123	47	4	12
		25-29	734	320	22	298	65	3	26
		30-34	867	422	29	273	101	12	30
		35+	799	523	11	140	85	14	26
	Years since diagnosis	5-9	222	89	8	59	44	6	16
		10-14	866	364	21	363	86	4	28
		15-19	933	479	33	284	98	11	28
		20+	818	501	19	168	92	13	25
	Age at diagnosis	1-4	70	39	2	22	7	.	.
		5-9	356	165	13	125	42	3	8
		10-14	1029	458	41	359	131	11	29
		15-20	1384	771	25	368	140	20	60
Males	**All cases**		**1468**	**740**	**48**	**443**	**168**	**21**	**48**
	Age at baseline	<18	42	13	.	19	8	.	2
		18-19	43	17	2	15	8	.	1
		20-24	210	84	13	72	30	3	8
		25-29	402	191	13	145	37	2	14
		30-34	433	205	18	133	54	10	13
		35+	338	230	2	59	31	6	10
	Years since diagnosis	5-9	127	52	2	34	25	4	10
		10-14	440	189	12	175	48	3	13
		15-19	495	251	25	143	52	8	16
		20+	406	248	9	91	43	6	9
	Age at diagnosis	1-4	52	29	2	15	6	.	.
		5-9	261	120	12	90	28	3	8
		10-14	525	229	26	179	71	5	15
		15-20	630	362	8	159	63	13	25
Females	**All cases**		**1371**	**693**	**33**	**431**	**152**	**13**	**49**
	Age at baseline	<18	13	6	1	2	4	.	.
		18-19	11	4	.	4	2	1	.
		20-24	120	44	3	51	17	1	4
		25-29	332	129	9	153	28	1	12
		30-34	434	217	11	140	47	2	17
		35+	461	293	9	81	54	8	16
	Years since diagnosis	5-9	95	37	6	25	19	2	6
		10-14	426	175	9	188	38	1	15
		15-19	438	228	8	141	46	3	12
		20+	412	253	10	77	49	7	16
	Age at diagnosis	1-4	18	10	.	7	1	.	.
		5-9	95	45	1	35	14	.	.
		10-14	504	229	15	180	60	6	14
		15-20	754	409	17	209	77	7	35

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
[1] Includes all alkylators with dose info, other than cisplatinum, carboplatin, DTIC and temozolomide
[2] Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Any chemotherapy			Alkylating agent (CED, mg/m2)[1]							
			All cases	Yes	No	Unknown	None	1-<4000 mg/m2	4000-<8000 mg/m2	8000-<12000 mg/m2	12000-<16000 mg/m2	16000-<20000 mg/m2	20000+ mg/m2	Unknown
Both sexes	**All cases**		**1933**	**1868**	**55**	**10**	**188**	**393**	**529**	**350**	**141**	**92**	**80**	**160**
	Age at baseline	<18	200	195	5	.	15	42	48	43	25	11	6	10
		18-19	119	117	1	1	4	23	35	21	12	9	3	12
		20-24	409	406	2	1	33	88	121	68	29	25	20	25
		25-29	533	518	10	5	47	110	141	103	43	25	17	47
		30-34	443	433	10	.	50	77	135	81	23	16	26	35
		35+	229	199	27	3	39	53	49	34	9	6	8	31
	Years since diagnosis	5-9	132	131	1	.	10	19	40	20	13	12	4	14
		10-14	608	590	16	2	55	131	169	119	51	34	13	36
		15-19	665	652	9	4	62	142	176	132	38	26	34	55
		20+	528	495	29	4	61	101	144	79	39	20	29	55
	Age at diagnosis	<1	12	10	2	.	3	3	2	1	.	.	2	1
		1-4	320	313	5	2	21	58	88	69	33	16	11	24
		5-9	588	579	6	3	48	125	152	102	49	35	27	50
		10-14	604	595	7	2	47	122	181	114	45	27	26	42
		15-20	409	371	35	3	69	85	106	64	14	14	14	43
Males	**All cases**		**1304**	**1257**	**42**	**5**	**128**	**252**	**393**	**234**	**88**	**61**	**55**	**93**
	Age at baseline	<18	138	135	3	.	10	27	37	33	14	8	4	5
		18-19	87	85	1	1	2	15	29	16	8	7	2	8
		20-24	268	266	2	.	22	53	88	43	17	21	12	12
		25-29	372	362	7	3	31	71	105	73	31	16	14	31
		30-34	291	282	9	.	34	55	99	50	11	6	17	19
		35+	148	127	20	1	29	31	35	19	7	3	6	18
	Years since diagnosis	5-9	99	98	1	.	6	14	31	16	10	10	4	8
		10-14	412	401	10	1	34	77	131	85	32	27	7	19
		15-19	433	424	8	1	43	92	125	88	21	15	22	27
		20+	360	334	23	3	45	69	106	45	25	9	22	39
	Age at diagnosis	<1	3	1	2	.	2	.	1	.	.	.	.	.
		1-4	215	210	4	1	15	37	65	47	16	11	9	15
		5-9	411	403	5	3	31	88	116	70	33	20	18	35
		10-14	412	407	5	.	33	76	136	73	30	22	19	23
		15-20	263	236	26	1	47	51	75	44	9	8	9	20
Females	**All cases**		**629**	**611**	**13**	**5**	**60**	**141**	**136**	**116**	**53**	**31**	**25**	**67**
	Age at baseline	<18	62	60	2	.	5	15	11	10	11	3	2	5
		18-19	32	32	.	.	2	8	6	5	4	2	1	4
		20-24	141	140	.	1	11	35	33	25	12	4	8	13
		25-29	161	156	3	2	16	39	36	30	12	9	3	16
		30-34	152	151	1	.	16	22	36	31	12	10	9	16
		35+	81	72	7	2	10	22	14	15	2	3	2	13
	Years since diagnosis	5-9	33	33	.	.	4	5	9	4	3	2	.	6
		10-14	196	189	6	1	21	54	38	34	19	7	6	17
		15-19	232	228	1	3	19	50	51	44	17	11	12	28
		20+	168	161	6	1	16	32	38	34	14	11	7	16
	Age at diagnosis	<1	9	9	.	.	1	3	1	1	.	.	2	1
		1-4	105	103	1	1	6	21	23	22	17	5	2	9

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
[1] Includes all alkylators with dose info, other than cisplatinum, carboplatin, DTIC and temozolomide
[2] Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Anthracyclines[2]					
			All cases	None	1-<100 mg/m2	100-<250 mg/m2	250-<400 mg/m2	400+ mg/m2	Unknown
Both sexes	**All cases**		**1933**	**516**	**174**	**809**	**226**	**98**	**110**
	Age at baseline	<18	200	50	16	97	23	6	8
		18-19	119	25	17	46	16	5	10
		20-24	409	104	39	191	39	19	17
		25-29	533	142	47	238	55	21	30
		30-34	443	120	37	170	59	32	25
		35+	229	75	18	67	34	15	20
	Years since diagnosis	5-9	132	33	6	50	25	8	10
		10-14	608	135	56	294	63	26	34
		15-19	665	171	82	264	75	38	35
		20+	528	177	30	201	63	26	31
	Age at diagnosis	<1	12	4	2	4	1	1	.
		1-4	320	88	26	147	34	12	13
		5-9	588	161	58	250	59	26	34
		10-14	604	164	50	265	66	30	29
		15-20	409	99	38	143	66	29	34
Males	**All cases**		**1304**	**374**	**109**	**552**	**149**	**60**	**60**
	Age at baseline	<18	138	37	10	67	17	4	3
		18-19	87	22	10	34	9	4	8
		20-24	268	70	22	131	24	13	8
		25-29	372	104	37	166	37	13	15
		30-34	291	84	20	112	38	21	16
		35+	148	57	10	42	24	5	10
	Years since diagnosis	5-9	99	25	6	40	19	5	4
		10-14	412	102	39	195	38	21	17
		15-19	433	117	46	182	51	20	17
		20+	360	130	18	135	41	14	22
	Age at diagnosis	<1	3	2	.	.	1	.	.
		1-4	215	63	16	97	22	9	8
		5-9	411	112	37	186	37	16	23
		10-14	412	123	31	181	43	19	15
		15-20	263	74	25	88	46	16	14
Females	**All cases**		**629**	**142**	**65**	**257**	**77**	**38**	**50**
	Age at baseline	<18	62	13	6	30	6	2	5
		18-19	32	3	7	12	7	1	2
		20-24	141	34	17	60	15	6	9
		25-29	161	38	10	72	18	8	15
		30-34	152	36	17	58	21	11	9
		35+	81	18	8	25	10	10	10
	Years since diagnosis	5-9	33	8	.	10	6	3	6
		10-14	196	33	17	99	25	5	17
		15-19	232	54	36	82	24	18	18
		20+	168	47	12	66	22	12	9
	Age at diagnosis	<1	9	2	2	4	.	1	.
		1-4	105	25	10	50	12	3	5

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
[1] Includes all alkylators with dose info, other than cisplatinum, carboplatin, DTIC and temozolomide
[2] Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Any chemotherapy			Alkylating agent (CED, mg/m2)[1]							
			All cases	Yes	No	Unknown	None	1-<4000 mg/m2	4000-<8000 mg/m2	8000-<12000 mg/m2	12000-<16000 mg/m2	16000-<20000 mg/m2	20000+ mg/m2	Unknown
		5-9	177	176	1	.	17	37	36	32	16	15	9	15
		10-14	192	188	2	2	14	46	45	41	15	5	7	19
		15-20	146	135	9	2	22	34	31	20	5	6	5	23

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
[1] Includes all alkylators with dose info, other than cisplatinum, carboplatin, DTIC and temozolomide
[2] Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Anthracyclines[2]					
			All cases	None	1-<100 mg/m2	100-<250 mg/m2	250-<400 mg/m2	400+ mg/m2	Unknown
		5-9	177	49	21	64	22	10	11
		10-14	192	41	19	84	23	11	14
		15-20	146	25	13	55	20	13	20

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
[1] Includes all alkylators with dose info, other than cisplatinum, carboplatin, DTIC and temozolomide
[2] Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Any chemotherapy			Alkylating agent (CED, mg/m2)[1]							
			All cases	Yes	No	Unknown	None	1-<4000 mg/m2	4000-<8000 mg/m2	8000-<12000 mg/m2	12000-<16000 mg/m2	16000-<20000 mg/m2	20000+ mg/m2	Unknown
Both sexes	**All cases**		**2087**	**2045**	**40**	**2**	**1850**	**41**	**70**	**38**	**30**	**8**	**26**	**24**
	Age at baseline	<18	762	742	20	.	671	21	30	15	5	3	11	6
		18-19	276	270	6	.	242	7	14	5	5	1	1	1
		20-24	616	606	9	1	551	8	18	11	12	2	7	7
		25-29	347	344	3	.	310	5	7	6	5	2	5	7
		30-34	69	67	1	1	62	.	1	.	3	.	1	2
		35+	17	16	1	.	14	.	.	1	.	.	1	1
	Years since diagnosis	5-9	168	166	2	.	138	3	7	2	3	.	8	7
		10-14	674	660	14	.	585	21	33	16	6	4	5	4
		15-19	685	670	14	1	601	11	24	16	15	2	9	7
		20+	560	549	10	1	526	6	6	4	6	2	4	6
	Age at diagnosis	<1	305	276	28	1	285	7	3	4	2	1	1	2
		1-4	1270	1261	9	.	1148	24	42	21	13	4	11	7
		5-9	436	434	2	.	366	8	21	11	10	2	12	6
		10-14	56	55	.	1	38	1	4	1	4	1	1	6
		15-20	20	19	1	.	13	1	.	1	1	.	1	3
Males	**All cases**		**924**	**903**	**20**	**1**	**821**	**16**	**30**	**19**	**14**	**3**	**12**	**9**
	Age at baseline	<18	370	359	11	.	321	10	18	7	4	2	6	2
		18-19	111	107	4	.	97	4	5	3	1	.	1	.
		20-24	255	250	4	1	235	1	5	4	6	.	1	3
		25-29	152	151	1	.	134	1	2	5	2	1	4	3
		30-34	29	29	.	.	28	.	.	.	1	.	.	.
		35+	7	7	.	.	6	.	.	.	.	.	.	1
	Years since diagnosis	5-9	75	74	1	.	57	1	5	2	3	.	5	2
		10-14	306	298	8	.	270	10	15	4	1	2	3	1
		15-19	292	284	8	.	260	4	8	9	6	.	3	2
		20+	251	247	3	1	234	1	2	4	4	1	1	4
	Age at diagnosis	<1	152	137	14	1	141	5	1	2	2	.	.	1
		1-4	567	561	6	.	512	8	20	11	7	2	5	2
		5-9	177	177	.	.	150	2	7	5	4	1	6	2
		10-14	20	20	.	.	13	1	2	1	.	.	.	3
		15-20	8	8	.	.	5	.	.	.	1	.	1	1
Females	**All cases**		**1163**	**1142**	**20**	**1**	**1029**	**25**	**40**	**19**	**16**	**5**	**14**	**15**
	Age at baseline	<18	392	383	9	.	350	11	12	8	1	1	5	4
		18-19	165	163	2	.	145	3	9	2	4	1	.	1
		20-24	361	356	5	.	316	7	13	7	6	2	6	4
		25-29	195	193	2	.	176	4	5	1	3	1	1	4
		30-34	40	38	1	1	34	.	1	.	2	.	1	2
		35+	10	9	1	.	8	.	.	1	.	.	1	.
	Years since diagnosis	5-9	93	92	1	.	81	2	2	.	.	.	3	5
		10-14	368	362	6	.	315	11	18	12	5	2	2	3
		15-19	393	386	6	1	341	7	16	7	9	2	6	5
		20+	309	302	7	.	292	5	4	.	2	1	3	2
	Age at diagnosis	<1	153	139	14	.	144	2	2	2	.	1	1	1
		1-4	703	700	3	.	636	16	22	10	6	2	6	5

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
[1] Includes all alkylators with dose info, other than cisplatinum, carboplatin, DTIC and temozolomide
[2] Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Anthracyclines[2]					
			All cases	None	1-<100 mg/m2	100-<250 mg/m2	250-<400 mg/m2	400+ mg/m2	Unknown
Both sexes	**All cases**		**2087**	**1124**	**84**	**475**	**330**	**25**	**49**
	Age at baseline	<18	762	386	35	179	133	11	18
		18-19	276	138	15	72	42	1	8
		20-24	616	345	13	141	95	7	15
		25-29	347	208	17	64	47	4	7
		30-34	69	37	4	14	12	1	1
		35+	17	10	.	5	1	1	.
	Years since diagnosis	5-9	168	78	3	34	43	2	8
		10-14	674	328	38	168	116	9	15
		15-19	685	359	22	186	97	6	15
		20+	560	359	21	87	74	8	11
	Age at diagnosis	<1	305	230	9	38	16	5	7
		1-4	1270	668	54	299	215	10	24
		5-9	436	199	18	115	83	8	13
		10-14	56	18	3	16	13	2	4
		15-20	20	9	.	7	3	.	1
Males	**All cases**		**924**	**514**	**29**	**208**	**141**	**13**	**19**
	Age at baseline	<18	370	193	9	94	60	5	9
		18-19	111	62	5	26	13	1	4
		20-24	255	148	5	51	44	4	3
		25-29	152	94	8	28	18	2	2
		30-34	29	13	2	8	5	.	1
		35+	7	4	.	1	1	1	.
	Years since diagnosis	5-9	75	36	1	16	17	1	4
		10-14	306	159	10	75	51	4	7
		15-19	292	164	7	76	39	2	4
		20+	251	155	11	41	34	6	4
	Age at diagnosis	<1	152	116	3	22	8	1	2
		1-4	567	300	19	131	100	7	10
		5-9	177	89	6	48	25	4	5
		10-14	20	4	1	5	7	1	2
		15-20	8	5	.	2	1	.	.
Females	**All cases**		**1163**	**610**	**55**	**267**	**189**	**12**	**30**
	Age at baseline	<18	392	193	26	85	73	6	9
		18-19	165	76	10	46	29	.	4
		20-24	361	197	8	90	51	3	12
		25-29	195	114	9	36	29	2	5
		30-34	40	24	2	6	7	1	.
		35+	10	6	.	4	.	.	.
	Years since diagnosis	5-9	93	42	2	18	26	1	4
		10-14	368	169	28	93	65	5	8
		15-19	393	195	15	110	58	4	11
		20+	309	204	10	46	40	2	7
	Age at diagnosis	<1	153	114	6	16	8	4	5
		1-4	703	368	35	168	115	3	14

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
[1] Includes all alkylators with dose info, other than cisplatinum, carboplatin, DTIC and temozolomide
[2] Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Any chemotherapy			Alkylating agent (CED, mg/m2)[1]							
			All cases	Yes	No	Unknown	None	1-<4000 mg/m2	4000-<8000 mg/m2	8000-<12000 mg/m2	12000-<16000 mg/m2	16000-<20000 mg/m2	20000+ mg/m2	Unknown
		5-9	259	257	2	.	216	6	14	6	6	1	6	4
		10-14	36	35	.	1	25	.	2	.	4	1	1	3
		15-20	12	11	1	.	8	1	.	1	.	.	.	2

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
[1] Includes all alkylators with dose info, other than cisplatinum, carboplatin, DTIC and temozolomide
[2] Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Anthracyclines[2]					
			All cases	None	1-<100 mg/m2	100-<250 mg/m2	250-<400 mg/m2	400+ mg/m2	Unknown
		5-9	259	110	12	67	58	4	8
		10-14	36	14	2	11	6	1	2
		15-20	12	4	.	5	2	.	1

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
[1] Includes all alkylators with dose info, other than cisplatinum, carboplatin, DTIC and temozolomide
[2] Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Any chemotherapy			Alkylating agent (CED, mg/m2)[1]							
			All cases	Yes	No	Unknown	None	1-<4000 mg/m2	4000-<8000 mg/m2	8000-<12000 mg/m2	12000-<16000 mg/m2	16000-<20000 mg/m2	20000+ mg/m2	Unknown
Both sexes	**All cases**		**1811**	**1102**	**695**	**14**	**716**	**181**	**312**	**129**	**118**	**74**	**117**	**164**
	Age at baseline	<18	890	548	337	5	346	113	159	66	47	25	55	79
		18-19	216	126	90	.	92	19	45	15	11	11	8	15
		20-24	511	317	191	3	199	35	90	36	47	25	31	48
		25-29	154	86	64	4	66	10	15	10	7	9	18	19
		30-34	34	22	10	2	10	4	2	2	5	3	5	3
		35+	6	3	3	.	3	.	1	.	1	1	.	.
	Years since diagnosis	5-9	152	111	39	2	42	14	21	16	6	6	20	27
		10-14	559	332	227	.	233	72	100	37	36	17	27	37
		15-19	594	348	241	5	245	58	108	45	40	28	27	43
		20+	506	311	188	7	196	37	83	31	36	23	43	57
	Age at diagnosis	<1	917	530	383	4	393	128	180	62	38	13	39	64
		1-4	713	458	248	7	257	46	116	55	64	47	57	71
		5-9	137	90	45	2	47	4	12	10	12	10	17	25
		10-14	27	14	12	1	12	2	2	2	2	2	2	3
		15-20	17	10	7	.	7	1	2	.	2	2	2	1
Males	**All cases**		**876**	**541**	**328**	**7**	**336**	**89**	**152**	**56**	**55**	**45**	**65**	**78**
	Age at baseline	<18	441	277	162	2	164	57	81	33	21	12	32	41
		18-19	94	58	36	.	36	6	21	5	6	9	5	6
		20-24	259	150	106	3	111	17	38	13	23	18	17	22
		25-29	66	43	21	2	22	6	11	5	1	4	9	8
		30-34	14	12	2	.	2	3	1	.	3	2	2	1
		35+	2	1	1	.	1	.	.	.	1	.	.	.
	Years since diagnosis	5-9	72	52	19	1	20	8	11	7	1	2	10	13
		10-14	275	168	107	.	108	38	48	20	17	8	17	19
		15-19	284	171	111	2	113	21	55	17	19	23	17	19
		20+	245	150	91	4	95	22	38	12	18	12	21	27
	Age at diagnosis	<1	472	268	202	2	206	68	89	32	17	7	22	31
		1-4	320	212	104	4	107	18	55	18	29	29	30	34
		5-9	68	52	15	1	16	2	8	5	8	6	10	13
		10-14	10	5	5	.	5	.	.	1	.	2	2	.
		15-20	6	4	2	.	2	1	.	.	1	1	1	.
Females	**All cases**		**935**	**561**	**367**	**7**	**380**	**92**	**160**	**73**	**63**	**29**	**52**	**86**
	Age at baseline	<18	449	271	175	3	182	56	78	33	26	13	23	38
		18-19	122	68	54	.	56	13	24	10	5	2	3	9
		20-24	252	167	85	.	88	18	52	23	24	7	14	26
		25-29	88	43	43	2	44	4	4	5	6	5	9	11
		30-34	20	10	8	2	8	1	1	2	2	1	3	2
		35+	4	2	2	.	2	.	1	.	.	1	.	.
	Years since diagnosis	5-9	80	59	20	1	22	6	10	9	5	4	10	14
		10-14	284	164	120	.	125	34	52	17	19	9	10	18
		15-19	310	177	130	3	132	37	53	28	21	5	10	24
		20+	261	161	97	3	101	15	45	19	18	11	22	30
	Age at diagnosis	<1	445	262	181	2	187	60	91	30	21	6	17	33
		1-4	393	246	144	3	150	28	61	37	35	18	27	37

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
[1] Includes all alkylators with dose info, other than cisplatinum, carboplatin, DTIC and temozolomide
[2] Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Anthracyclines[2]					
			All cases	None	1-<100 mg/m2	100-<250 mg/m2	250-<400 mg/m2	400+ mg/m2	Unknown
Both sexes	**All cases**		**1811**	**1039**	**137**	**424**	**105**	**38**	**68**
	Age at baseline	<18	890	473	99	220	56	10	32
		18-19	216	127	6	54	11	7	11
		20-24	511	310	25	119	28	13	16
		25-29	154	104	6	23	8	5	8
		30-34	34	22	1	6	2	2	1
		35+	6	3	.	2	.	1	.
	Years since diagnosis	5-9	152	61	14	42	20	6	9
		10-14	559	301	62	147	26	6	17
		15-19	594	346	39	138	37	10	24
		20+	506	331	22	97	22	16	18
	Age at diagnosis	<1	917	579	83	187	30	16	22
		1-4	713	368	48	192	57	13	35
		5-9	137	69	4	36	15	5	8
		10-14	27	15	1	4	2	2	3
		15-20	17	8	1	5	1	2	.
Males	**All cases**		**876**	**477**	**72**	**226**	**56**	**16**	**29**
	Age at baseline	<18	441	221	53	118	31	3	15
		18-19	94	50	3	29	6	2	4
		20-24	259	157	13	59	14	8	8
		25-29	66	41	2	15	4	2	2
		30-34	14	7	1	4	1	1	.
		35+	2	1	.	1	.	.	.
	Years since diagnosis	5-9	72	27	4	21	12	3	5
		10-14	275	141	36	79	12	1	6
		15-19	284	155	22	73	22	3	9
		20+	245	154	10	53	10	9	9
	Age at diagnosis	<1	472	290	45	105	14	7	11
		1-4	320	151	25	96	28	4	16
		5-9	68	29	2	21	11	3	2
		10-14	10	5	.	2	2	1	.
		15-20	6	2	.	2	1	1	.
Females	**All cases**		**935**	**562**	**65**	**198**	**49**	**22**	**39**
	Age at baseline	<18	449	252	46	102	25	7	17
		18-19	122	77	3	25	5	5	7
		20-24	252	153	12	60	14	5	8
		25-29	88	63	4	8	4	3	6
		30-34	20	15	.	2	1	1	1
		35+	4	2	.	1	.	1	.
	Years since diagnosis	5-9	80	34	10	21	8	3	4
		10-14	284	160	26	68	14	5	11
		15-19	310	191	17	65	15	7	15
		20+	261	177	12	44	12	7	9
	Age at diagnosis	<1	445	289	38	82	16	9	11
		1-4	393	217	23	96	29	9	19

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
[1] Includes all alkylators with dose info, other than cisplatinum, carboplatin, DTIC and temozolomide
[2] Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Any chemotherapy			Alkylating agent (CED, mg/m2)[1]							
			All cases	Yes	No	Unknown	None	1-<4000 mg/m2	4000-<8000 mg/m2	8000-<12000 mg/m2	12000-<16000 mg/m2	16000-<20000 mg/m2	20000+ mg/m2	Unknown
		5-9	69	38	30	1	31	2	4	5	4	4	7	12
		10-14	17	9	7	1	7	2	2	1	2	.	.	3
		15-20	11	6	5	.	5	.	2	.	1	1	1	1

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
[1] Includes all alkylators with dose info, other than cisplatinum, carboplatin, DTIC and temozolomide
[2] Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Anthracyclines[2]					
			All cases	None	1-<100 mg/m2	100-<250 mg/m2	250-<400 mg/m2	400+ mg/m2	Unknown
		5-9	69	40	2	15	4	2	6
		10-14	17	10	1	2	.	1	3
		15-20	11	6	1	3	.	1	.

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
[1] Includes all alkylators with dose info, other than cisplatinum, carboplatin, DTIC and temozolomide
[2] Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Any chemotherapy			Alkylating agent (CED, mg/m2)[1]							
			All cases	Yes	No	Unknown	None	1-<4000 mg/m2	4000-<8000 mg/m2	8000-<12000 mg/m2	12000-<16000 mg/m2	16000-<20000 mg/m2	20000+ mg/m2	Unknown
Both sexes	**All cases**		**1596**	**1349**	**237**	**10**	**453**	**68**	**103**	**162**	**148**	**151**	**362**	**149**
	Age at baseline	<18	313	289	23	1	62	12	21	39	45	37	74	23
		18-19	115	106	8	1	22	4	7	16	9	21	28	8
		20-24	383	342	39	2	88	14	22	38	40	39	104	38
		25-29	354	302	49	3	101	16	26	33	36	31	79	32
		30-34	267	206	60	1	98	14	12	24	13	18	59	29
		35+	164	104	58	2	82	8	15	12	5	5	18	19
	Years since diagnosis	5-9	165	137	27	1	45	8	15	15	20	16	27	19
		10-14	473	397	74	2	132	19	33	55	48	45	107	34
		15-19	499	441	56	2	117	22	30	56	44	55	128	47
		20+	459	374	80	5	159	19	25	36	36	35	100	49
	Age at diagnosis	<1	108	86	21	1	40	6	5	10	13	12	14	8
		1-4	513	490	20	3	85	14	37	62	61	67	141	46
		5-9	361	326	34	1	90	18	16	36	34	36	102	29
		10-14	313	251	59	3	100	12	19	26	27	22	72	35
		15-20	301	196	103	2	138	18	26	28	13	14	33	31
Males	**All cases**		**853**	**743**	**107**	**3**	**234**	**37**	**60**	**75**	**75**	**77**	**214**	**81**
	Age at baseline	<18	179	170	9	.	28	8	15	20	25	16	52	15
		18-19	58	55	3	.	10	1	3	9	3	15	14	3
		20-24	214	189	24	1	57	8	12	18	21	17	59	22
		25-29	182	161	20	1	50	10	13	13	17	16	48	15
		30-34	141	114	26	1	50	7	8	8	8	11	33	16
		35+	79	54	25	.	39	3	9	7	1	2	8	10
	Years since diagnosis	5-9	89	77	12	.	21	4	9	7	11	7	19	11
		10-14	264	229	35	.	65	12	21	27	24	22	73	20
		15-19	253	229	22	2	62	14	14	24	21	30	65	23
		20+	247	208	38	1	86	7	16	17	19	18	57	27
	Age at diagnosis	<1	44	38	6	.	13	3	3	7	4	5	5	4
		1-4	298	285	12	1	51	6	23	31	38	35	85	29
		5-9	203	183	19	1	53	13	9	16	16	19	62	15
		10-14	167	140	26	1	53	7	11	9	12	12	45	18
		15-20	141	97	44	.	64	8	14	12	5	6	17	15
Females	**All cases**		**743**	**606**	**130**	**7**	**219**	**31**	**43**	**87**	**73**	**74**	**148**	**68**
	Age at baseline	<18	134	119	14	1	34	4	6	19	20	21	22	8
		18-19	57	51	5	1	12	3	4	7	6	6	14	5
		20-24	169	153	15	1	31	6	10	20	19	22	45	16
		25-29	172	141	29	2	51	6	13	20	19	15	31	17
		30-34	126	92	34	.	48	7	4	16	5	7	26	13
		35+	85	50	33	2	43	5	6	5	4	3	10	9
	Years since diagnosis	5-9	76	60	15	1	24	4	6	8	9	9	8	8
		10-14	209	168	39	2	67	7	12	28	24	23	34	14
		15-19	246	212	34	.	55	8	16	32	23	25	63	24
		20+	212	166	42	4	73	12	9	19	17	17	43	22
	Age at diagnosis	<1	64	48	15	1	27	3	2	3	9	7	9	4
		1-4	215	205	8	2	34	8	14	31	23	32	56	17

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
[1] Includes all alkylators with dose info, other than cisplatinum, carboplatin, DTIC and temozolomide
[2] Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Anthracyclines[2]					
			All cases	None	1-<100 mg/m2	100-<250 mg/m2	250-<400 mg/m2	400+ mg/m2	Unknown
Both sexes	**All cases**		**1596**	**937**	**34**	**129**	**255**	**182**	**59**
	Age at baseline	<18	313	162	8	30	65	40	8
		18-19	115	70	5	6	16	16	2
		20-24	383	236	2	31	65	36	13
		25-29	354	205	6	28	63	38	14
		30-34	267	164	7	20	31	31	14
		35+	164	100	6	14	15	21	8
	Years since diagnosis	5-9	165	66	1	19	45	26	8
		10-14	473	269	13	32	85	56	18
		15-19	499	298	11	42	69	63	16
		20+	459	304	9	36	56	37	17
	Age at diagnosis	<1	108	79	3	4	10	9	3
		1-4	513	291	12	47	90	58	15
		5-9	361	232	7	23	60	32	7
		10-14	313	167	3	29	52	45	17
		15-20	301	168	9	26	43	38	17
Males	**All cases**		**853**	**501**	**21**	**66**	**140**	**94**	**31**
	Age at baseline	<18	179	88	6	20	42	19	4
		18-19	58	38	3	1	9	7	.
		20-24	214	135	1	14	37	20	7
		25-29	182	109	3	13	27	22	8
		30-34	141	87	3	9	18	15	9
		35+	79	44	5	9	7	11	3
	Years since diagnosis	5-9	89	31	.	12	25	17	4
		10-14	264	148	11	19	48	30	8
		15-19	253	156	5	14	42	28	8
		20+	247	166	5	21	25	19	11
	Age at diagnosis	<1	44	30	1	3	5	3	2
		1-4	298	172	8	21	58	31	8
		5-9	203	137	3	15	31	13	4
		10-14	167	85	3	15	23	32	9
		15-20	141	77	6	12	23	15	8
Females	**All cases**		**743**	**436**	**13**	**63**	**115**	**88**	**28**
	Age at baseline	<18	134	74	2	10	23	21	4
		18-19	57	32	2	5	7	9	2
		20-24	169	101	1	17	28	16	6
		25-29	172	96	3	15	36	16	6
		30-34	126	77	4	11	13	16	5
		35+	85	56	1	5	8	10	5
	Years since diagnosis	5-9	76	35	1	7	20	9	4
		10-14	209	121	2	13	37	26	10
		15-19	246	142	6	28	27	35	8
		20+	212	138	4	15	31	18	6
	Age at diagnosis	<1	64	49	2	1	5	6	1
		1-4	215	119	4	26	32	27	7

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
[1] Includes all alkylators with dose info, other than cisplatinum, carboplatin, DTIC and temozolomide
[2] Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Any chemotherapy			Alkylating agent (CED, mg/m2)[1]							
			All cases	Yes	No	Unknown	None	1-<4000 mg/m2	4000-<8000 mg/m2	8000-<12000 mg/m2	12000-<16000 mg/m2	16000-<20000 mg/m2	20000+ mg/m2	Unknown
		5-9	158	143	15	.	37	5	7	20	18	17	40	14
		10-14	146	111	33	2	47	5	8	17	15	10	27	17
		15-20	160	99	59	2	74	10	12	16	8	8	16	16

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
[1] Includes all alkylators with dose info, other than cisplatinum, carboplatin, DTIC and temozolomide
[2] Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Anthracyclines[2]					
			All cases	None	1-<100 mg/m2	100-<250 mg/m2	250-<400 mg/m2	400+ mg/m2	Unknown
		5-9	158	95	4	8	29	19	3
		10-14	146	82	.	14	29	13	8
		15-20	160	91	3	14	20	23	9

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
[1] Includes all alkylators with dose info, other than cisplatinum, carboplatin, DTIC and temozolomide
[2] Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Any chemotherapy			Alkylating agent (CED, mg/m2)[1]							
			All cases	Yes	No	Unknown	None	1-<4000 mg/m2	4000-<8000 mg/m2	8000-<12000 mg/m2	12000-<16000 mg/m2	16000-<20000 mg/m2	20000+ mg/m2	Unknown
Both sexes	**All cases**		**1937**	**1792**	**138**	**7**	**468**	**160**	**329**	**217**	**178**	**124**	**295**	**166**
	Age at baseline	<18	85	84	1	.	5	5	9	6	12	6	25	17
		18-19	66	61	5	.	10	5	8	8	10	5	11	9
		20-24	360	347	12	1	44	29	68	42	32	33	74	38
		25-29	528	500	27	1	138	35	88	67	42	38	79	41
		30-34	521	476	43	2	152	46	86	55	54	19	77	32
		35+	377	324	50	3	119	40	70	39	28	23	29	29
	Years since diagnosis	5-9	216	209	6	1	21	16	53	18	22	13	31	42
		10-14	630	582	47	1	148	60	98	85	56	36	107	40
		15-19	635	595	37	3	172	42	102	67	60	40	107	45
		20+	456	406	48	2	127	42	76	47	40	35	50	39
	Age at diagnosis	<1	8	7	1	.	2	.	.	1	2	1	2	.
		1-4	80	78	2	.	10	4	7	4	11	8	27	9
		5-9	337	319	18	.	60	16	51	40	42	33	64	31
		10-14	776	734	39	3	180	70	129	86	66	51	122	72
		15-20	736	654	78	4	216	70	142	86	57	31	80	54
Males	**All cases**		**983**	**921**	**58**	**4**	**225**	**74**	**174**	**116**	**87**	**63**	**161**	**83**
	Age at baseline	<18	43	43	.	.	3	1	5	2	6	3	14	9
		18-19	33	30	3	.	6	3	2	6	6	2	3	5
		20-24	175	168	6	1	20	12	33	24	17	15	36	18
		25-29	274	260	13	1	73	15	43	37	22	22	40	22
		30-34	258	241	16	1	67	24	45	24	25	10	49	14
		35+	200	179	20	1	56	19	46	23	11	11	19	15
	Years since diagnosis	5-9	115	111	3	1	11	8	27	9	14	6	20	20
		10-14	319	296	22	1	81	23	55	48	27	15	47	23
		15-19	323	308	14	1	81	24	51	37	28	21	59	22
		20+	226	206	19	1	52	19	41	22	18	21	35	18
	Age at diagnosis	<1	4	4	.	.	1	.	.	1	.	.	2	.
		1-4	41	39	2	.	4	1	4	2	8	5	13	4
		5-9	172	162	10	.	29	7	24	24	17	20	35	16
		10-14	364	348	14	2	78	25	56	42	38	26	63	36
		15-20	402	368	32	2	113	41	90	47	24	12	48	27
Females	**All cases**		**954**	**871**	**80**	**3**	**243**	**86**	**155**	**101**	**91**	**61**	**134**	**83**
	Age at baseline	<18	42	41	1	.	2	4	4	4	6	3	11	8
		18-19	33	31	2	.	4	2	6	2	4	3	8	4
		20-24	185	179	6	.	24	17	35	18	15	18	38	20
		25-29	254	240	14	.	65	20	45	30	20	16	39	19
		30-34	263	235	27	1	85	22	41	31	29	9	28	18
		35+	177	145	30	2	63	21	24	16	17	12	10	14
	Years since diagnosis	5-9	101	98	3	.	10	8	26	9	8	7	11	22
		10-14	311	286	25	.	67	37	43	37	29	21	60	17
		15-19	312	287	23	2	91	18	51	30	32	19	48	23
		20+	230	200	29	1	75	23	35	25	22	14	15	21
	Age at diagnosis	<1	4	3	1	.	1	.	.	.	2	1	.	.
		1-4	39	39	.	.	6	3	3	2	3	3	14	5

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
[1] Includes all alkylators with dose info, other than cisplatinum, carboplatin, DTIC and temozolomide
[2] Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Anthracyclines[2]					
			All cases	None	1-<100 mg/m2	100-<250 mg/m2	250-<400 mg/m2	400+ mg/m2	Unknown
Both sexes	**All cases**		**1937**	**230**	**37**	**196**	**737**	**588**	**149**
	Age at baseline	<18	85	2	.	11	43	20	9
		18-19	66	7	1	4	27	20	7
		20-24	360	20	7	27	167	117	22
		25-29	528	51	10	54	203	163	47
		30-34	521	70	12	54	182	167	36
		35+	377	80	7	46	115	101	28
	Years since diagnosis	5-9	216	13	6	13	92	69	23
		10-14	630	59	8	68	259	201	35
		15-19	635	63	11	70	232	211	48
		20+	456	95	12	45	154	107	43
	Age at diagnosis	<1	8	2	1	4	1	.	.
		1-4	80	5	1	7	47	14	6
		5-9	337	30	6	28	143	100	30
		10-14	776	85	11	78	311	233	58
		15-20	736	108	18	79	235	241	55
Males	**All cases**		**983**	**100**	**21**	**105**	**358**	**316**	**83**
	Age at baseline	<18	43	1	.	7	17	12	6
		18-19	33	5	1	2	11	11	3
		20-24	175	10	3	15	74	60	13
		25-29	274	23	4	30	98	90	29
		30-34	258	26	8	26	94	86	18
		35+	200	35	5	25	64	57	14
	Years since diagnosis	5-9	115	7	3	7	44	39	15
		10-14	319	26	3	38	120	110	22
		15-19	323	25	8	36	119	109	26
		20+	226	42	7	24	75	58	20
	Age at diagnosis	<1	4	1	1	1	1	.	.
		1-4	41	4	1	5	21	9	1
		5-9	172	17	2	16	67	53	17
		10-14	364	33	4	39	137	115	36
		15-20	402	45	13	44	132	139	29
Females	**All cases**		**954**	**130**	**16**	**91**	**379**	**272**	**66**
	Age at baseline	<18	42	1	.	4	26	8	3
		18-19	33	2	.	2	16	9	4
		20-24	185	10	4	12	93	57	9
		25-29	254	28	6	24	105	73	18
		30-34	263	44	4	28	88	81	18
		35+	177	45	2	21	51	44	14
	Years since diagnosis	5-9	101	6	3	6	48	30	8
		10-14	311	33	5	30	139	91	13
		15-19	312	38	3	34	113	102	22
		20+	230	53	5	21	79	49	23
	Age at diagnosis	<1	4	1	.	3	.	.	.
		1-4	39	1	.	2	26	5	5

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
[1] Includes all alkylators with dose info, other than cisplatinum, carboplatin, DTIC and temozolomide
[2] Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Any chemotherapy			Alkylating agent (CED, mg/m2)[1]							
			All cases	Yes	No	Unknown	None	1-<4000 mg/m2	4000-<8000 mg/m2	8000-<12000 mg/m2	12000-<16000 mg/m2	16000-<20000 mg/m2	20000+ mg/m2	Unknown
		5-9	165	157	8	.	31	9	27	16	25	13	29	15
		10-14	412	386	25	1	102	45	73	44	28	25	59	36
		15-20	334	286	46	2	103	29	52	39	33	19	32	27

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
[1] Includes all alkylators with dose info, other than cisplatinum, carboplatin, DTIC and temozolomide
[2] Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Anthracyclines[2]					
			All cases	None	1-<100 mg/m2	100-<250 mg/m2	250-<400 mg/m2	400+ mg/m2	Unknown
		5-9	165	13	4	12	76	47	13
		10-14	412	52	7	39	174	118	22
		15-20	334	63	5	35	103	102	26

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
[1] Includes all alkylators with dose info, other than cisplatinum, carboplatin, DTIC and temozolomide
[2] Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Any chemotherapy			Alkylating agent (CED, mg/m2)[1]							
			All cases	Yes	No	Unknown	None	1-<4000 mg/m2	4000-<8000 mg/m2	8000-<12000 mg/m2	12000-<16000 mg/m2	16000-<20000 mg/m2	20000+ mg/m2	Unknown
Both sexes	**All cases**		**686**	**680**	**4**	**2**	**15**	**21**	**38**	**84**	**105**	**95**	**242**	**86**
	Age at baseline	<18	54	54	.	.	1	.	3	5	9	4	21	11
		18-19	33	33	.	.	.	2	.	5	9	4	8	5
		20-24	157	155	1	1	4	3	6	18	21	23	62	20
		25-29	193	193	.	.	4	7	12	25	20	33	69	23
		30-34	154	151	2	1	2	7	9	15	29	13	59	20
		35+	95	94	1	.	4	2	8	16	17	18	23	7
	Years since diagnosis	5-9	91	89	1	1	2	2	9	7	12	7	27	25
		10-14	231	231	.	.	4	10	8	39	39	29	86	16
		15-19	214	213	.	1	2	4	11	21	26	33	88	29
		20+	150	147	3	.	7	5	10	17	28	26	41	16
	Age at diagnosis	<1	4	4	.	.	1	.	.	.	1	1	1	.
		1-4	50	50	.	.	1	.	1	2	10	7	21	8
		5-9	169	167	2	.	3	5	9	23	28	27	56	18
		10-14	258	255	2	1	9	11	9	26	33	35	100	35
		15-20	205	204	.	1	1	5	19	33	33	25	64	25
Males	**All cases**		**354**	**351**	**2**	**1**	**7**	**11**	**20**	**44**	**55**	**47**	**134**	**36**
	Age at baseline	<18	24	24	.	.	1	.	.	1	5	1	12	4
		18-19	17	17	.	.	.	1	.	4	6	2	2	2
		20-24	79	78	.	1	1	2	2	10	12	11	30	11
		25-29	99	99	.	.	3	3	4	14	11	19	35	10
		30-34	83	82	1	.	1	4	7	5	14	7	39	6
		35+	52	51	1	.	1	1	7	10	7	7	16	3
	Years since diagnosis	5-9	49	48	.	1	1	1	2	3	9	3	18	12
		10-14	109	109	.	.	2	4	4	22	18	13	37	9
		15-19	116	116	.	.	2	4	6	12	15	16	50	11
		20+	80	78	2	.	2	2	8	7	13	15	29	4
	Age at diagnosis	<1	2	2	.	.	1	.	.	.	.	.	1	.
		1-4	26	26	.	.	.	.	.	.	8	4	11	3
		5-9	83	82	1	.	1	3	4	12	12	17	29	5
		10-14	136	134	1	1	4	5	4	15	21	17	53	17
		15-20	107	107	.	.	1	3	12	17	14	9	40	11
Females	**All cases**		**332**	**329**	**2**	**1**	**8**	**10**	**18**	**40**	**50**	**48**	**108**	**50**
	Age at baseline	<18	30	30	.	.	.	.	3	4	4	3	9	7
		18-19	16	16	.	.	.	1	.	1	3	2	6	3
		20-24	78	77	1	.	3	1	4	8	9	12	32	9
		25-29	94	94	.	.	1	4	8	11	9	14	34	13
		30-34	71	69	1	1	1	3	2	10	15	6	20	14
		35+	43	43	.	.	3	1	1	6	10	11	7	4
	Years since diagnosis	5-9	42	41	1	.	1	1	7	4	3	4	9	13
		10-14	122	122	.	.	2	6	4	17	21	16	49	7
		15-19	98	97	.	1	.	.	5	9	11	17	38	18
		20+	70	69	1	.	5	3	2	10	15	11	12	12
	Age at diagnosis	<1	2	2	.	.	.	.	.	.	1	1	.	.
		1-4	24	24	.	.	1	.	1	2	2	3	10	5

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
[1] Includes all alkylators with dose info, other than cisplatinum, carboplatin, DTIC and temozolomide
[2] Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Anthracyclines[2]					
			All cases	None	1-<100 mg/m2	100-<250 mg/m2	250-<400 mg/m2	400+ mg/m2	Unknown
Both sexes	**All cases**		**686**	**57**	**10**	**59**	**336**	**171**	**53**
	Age at baseline	<18	54	1	.	6	30	13	4
		18-19	33	2	1	4	14	9	3
		20-24	157	5	.	10	83	43	16
		25-29	193	14	5	16	103	41	14
		30-34	154	20	2	11	68	42	11
		35+	95	15	2	12	38	23	5
	Years since diagnosis	5-9	91	5	3	1	38	31	13
		10-14	231	5	3	25	126	64	8
		15-19	214	16	1	20	109	52	16
		20+	150	31	3	13	63	24	16
	Age at diagnosis	<1	4	1	.	3	.	.	.
		1-4	50	2	.	4	34	5	5
		5-9	169	12	1	13	88	38	17
		10-14	258	30	3	23	125	59	18
		15-20	205	12	6	16	89	69	13
Males	**All cases**		**354**	**24**	**5**	**33**	**177**	**91**	**24**
	Age at baseline	<18	24	1	.	4	11	7	1
		18-19	17	2	1	2	5	6	1
		20-24	79	1	.	6	42	21	9
		25-29	99	6	1	9	54	22	7
		30-34	83	6	1	5	44	23	4
		35+	52	8	2	7	21	12	2
	Years since diagnosis	5-9	49	2	2	1	18	18	8
		10-14	109	2	.	14	58	31	4
		15-19	116	4	1	10	65	29	7
		20+	80	16	2	8	36	13	5
	Age at diagnosis	<1	2	1	.	1	.	.	.
		1-4	26	2	.	3	17	4	.
		5-9	83	6	.	7	43	20	7
		10-14	136	12	2	14	69	29	10
		15-20	107	3	3	8	48	38	7
Females	**All cases**		**332**	**33**	**5**	**26**	**159**	**80**	**29**
	Age at baseline	<18	30	.	.	2	19	6	3
		18-19	16	.	.	2	9	3	2
		20-24	78	4	.	4	41	22	7
		25-29	94	8	4	7	49	19	7
		30-34	71	14	1	6	24	19	7
		35+	43	7	.	5	17	11	3
	Years since diagnosis	5-9	42	3	1	.	20	13	5
		10-14	122	3	3	11	68	33	4
		15-19	98	12	.	10	44	23	9
		20+	70	15	1	5	27	11	11
	Age at diagnosis	<1	2	.	.	2	.	.	.
		1-4	24	.	.	1	17	1	5

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
[1] Includes all alkylators with dose info, other than cisplatinum, carboplatin, DTIC and temozolomide
[2] Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Any chemotherapy			Alkylating agent (CED, mg/m2)[1]							
			All cases	Yes	No	Unknown	None	1-<4000 mg/m2	4000-<8000 mg/m2	8000-<12000 mg/m2	12000-<16000 mg/m2	16000-<20000 mg/m2	20000+ mg/m2	Unknown
		5-9	86	85	1	.	2	2	5	11	16	10	27	13
		10-14	122	121	1	.	5	6	5	11	12	18	47	18
		15-20	98	97	.	1	.	2	7	16	19	16	24	14

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
[1] Includes all alkylators with dose info, other than cisplatinum, carboplatin, DTIC and temozolomide
[2] Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Anthracyclines[2]				
			All cases	None	1-<100 mg/m2	100-<250 mg/m2	250-<400 mg/m2	400+ mg/m2	Unknown
		5-9	86	6	1	6	45	18	10
		10-14	122	18	1	9	56	30	8
		15-20	98	9	3	8	41	31	6

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
[1] Includes all alkylators with dose info, other than cisplatinum, carboplatin, DTIC and temozolomide
[2] Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)